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ABSTRACT 
 Adenosine is a pleotropic purine nucleoside with actions ranging from neurotransmission 
to immunomodulation. Pathologic processes that trigger cellular stress and damage also cause 
significant increases in local and systemic concentrations of adenosine. Coinciding with 
elevation in adenosine is an increase in brain-based IL-1. Perturbed cognition appears to be a 
sequela of acute hypoxia but the mechanisms by which cognitive functions are impacted are not 
clearly defined. In this study, we first examined the impact of acute hypoxia on learning and 
memory and its relationship to the inflammasome. Mice were exposed to normobaric 6% 
oxygen/ 94% nitrogen for 2 hours (hypoxia) or ambient air (normoxia). Mice required 6 hrs of 
reoxygenation before they could be successfully trained in novel object recognition post-
hypoxia. Mice also lost the ability to be fear conditioned if trained post-hypoxia. When mice 
were administered interleukin-1 receptor antagonist prior to hypoxia, mice could be successfully 
trained in novel object recognition 4 hrs post-hypoxia. Post hypoxia learning also recovered in 4 
hrs in IL-1 receptor 1 knock-out mice. Importantly, when the caspase-1 inhibitor, YVAD-CMK, 
was administered by intracerebroventricular (i.c.v.) injection into the brain, post-hypoxia 
learning recovered in 4 hrs. Similarly, the administration of the adenosine receptor (AR) 
antagonist, caffeine, expedited recovery from anterograde amnesia. Furthermore, 
hypoxia/reoxygenation more than doubled brain caspase 1 activity, while adenosine alone was 
able to elicit a similar response. This reoxygenation-dependent activation of caspase 1 was 
prevented by administration of either caffeine or by targeted antagonism of A1/A2A ARs. These 
findings suggest that anterograde amnesia after hypoxia/reoxygenation is reliant, in part, on IL-
1β generated by AR-dependent activation of caspase 1 after reoxygenation. 
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 Next, we set out to investigate the signaling pathway in which adenosine can trigger 
caspase-1 activation. Here, we show that mice perfused with 50 μm adenosine demonstrate a 
brain-based increase in IL-1β and caspase-1 activity coupled to increases in intracellular cAMP 
and PKA activity. Co-perfusion of adenosine with the adenosine A2A receptor antagonist, 8-(3-
Chlorostyryl)-caffeine, prevented adenosine-dependent activation of caspase-1 as did use of 
adenosine A2A receptor knockout (KO) mice. Co-perfusion of adenosine with the KATP channel 
blocker, glyburide, also blocked adenosine-dependent activation of caspase-1. Finally, mice i.p. 
injected with 50 μm adenosine displayed reduced locomotor activity and food intake and 
increase anxiety-like bahviors. These adenosine-dependent behaviors were prevented in caspase-
1, IL-1R1 and adenosine A2A receptor KO mice. Furthermore, when mice were injected with the 
caspase-1 inhibitor, Ac-YVAD-CMK, i.c.v., they were protected against a peripheral injection of 
adenosine, suggesting that brain-based IL-1β induction is required after adenosine 
administration. Taken together, our data indicate that adenosine & the adenosine A2A receptor 
promotes immobility, anorexia, and anxiety via PKA-mediated KATP channel opening and 
subsequent K+ efflux-dependent activation of the inflammasome that is unique to the brain.  
 Lastly, we tested the interaction between hypoxia/reoxygenation and adenosine 
dependent anxiety-like behaviors. Similar to before, mice were exposed to 6% oxygen for 2 
hours and allowed to recover. We see that hypoxia/reoxygenation elicited over 2.5-fold increase 
in circulating adenosine levels, which returned to normal 2 hours after hypoxia. This increase 
was mirrored with an elevation in active caspase-1 staining in neurons of the amygdala but not 
the hippocampus, suggesting a region specific upregulation. Furthermore, we see that 
hypoxia/reoxygenation and subsequent increase in circulating adenosine was anxiogenic in WT 
animals, while A2A AR KO animals were protected, further suggesting the role of adenosine in 
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hypoxia/reoxygenation-induced anxiety-like behaviors. Taken together, the data suggests that 
hypoxia/reoxygenation induces an upregulation in neuron-based caspase-1 via A2A AR 
signaling in the amygdala, which subsequently can cause amnesia and anxiety.  
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CHAPTER 1: LITERATURE REVIEW 
Abstract 
 Adenosine is a pleiotropic neuromodulator that acts as a signal during states of energy 
imbalance. It functions through four (A1, A2A, A2B, A3) cell surface G protein-coupled 
adenosine receptors (AR) to inhibit (A1 and A3) or stimulate (A2A and A2B) adenylyl cyclase 
and subsequently change cAMP concentration. Physiological concentration of extracellular 
adenosine exerts inhibitory effects on neurons and decrease neurotransmission as a possible 
neuroprotective mechanism to prevent overexcitation. However, many disease states have been 
associated with an elevated concentration of adenosine that can activate pathological pathways 
where prolong inflammation and cellular damage can occur. The duality of action yielded many 
hypotheses of possible mechanisms involved in adenosine signaling. This review will explore the 
various influences adenosine has on many systemic and neurological diseases and propose 
possible novel therapies. 
 
Introduction 
Adenosine is an endogenous purine nucleoside that has been shown to work through four 
G protein-coupled receptors; where two (A1 and A3) are shown to inhibit and two activate (A2A 
and A2B) adenylyl cyclase to cause changes in cAMP concentration. Under physiological 
conditions, adenosine, as a metabolic intermediary of ATP breakdown, serves as a 
neuromodulator (Fredholm et al., 1994). Adenosine exhibits various tonic effects throughout the 
body, however, this review will be focused on diseases pertaining energy imbalance and the 
neurological disorders, where it is tied to functions including sleep (Portas et al., 1997), arousal 
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(Lin et al., 1997) and memory (Pereira et al., 2005). Extracellular concentrations fluctuate, 
yielding highest during wakefulness (30 nM) than during sleep (24 nM) (Porkka-Heiskanen, 
1997, Huston et al., 1996). However, during metabolic and cellular stress caused by 
inflammatory responses, extracellular ATP, ADP, and AMP can be quickly phosphohydrolyzed 
to adenosine in the interstitial space by ecto-5’-nucleotidase, also known as CD73 (Hart et al., 
2008; Kobie et al., 2006; Riksen et al., 2006). Here, we review the function of extracellular 
adenosine and discuss the potential impact on diseases and possible interventions through the 
paradoxical adenosine signaling.  
 
Purine and adenosine metabolism 
 Extracellular purine nucleotides and nucleosiÞs can act as signaling molecules (Ralevic 
& Burnstock, 1998; Zimmermann. 2000). Metabolism of these purines is presumed in all tissues 
and most cell types to inactivate these signals via cell-surface enzymes. Fig.1.1 summarized the 
mechanism of purine degradation in the intra- and extracellular fraction. Due to the size and 
charge of ATP, it cannot diffuse through cell membranes and require precise regulation on 
release via cytolysis, vesicular release, or activation of transport proteins. Intracellular ATP 
concentration is usually around 1 mM while extracellular concentration remains comparatively 
low (μM concentration) (Corriden & Insel, 2010). On the contrary, adenosine concentration 
remains relatively balanced across the membrane (between 20-30 nM) (Porkka-Heiskanen, 1997, 
Huston et al., 1996) due to greater permeability via adenosine transporters (Deussen et al., 1999) 
and production can be attributed to both intra- and extracellular metabolism of ATP.  
 The hydrolysis of ATP and ADP to AMP is primarily catalyzed by ATP-
diphosphohydrolase, also known as apyrase, with extracellular Km values between 10-20 µM 
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(Zimmermann, 1996), while specific ATP- and ADPases and ecto-nucleotide pyrophosphatases 
may also produce AMP. Furthermore, formation of ATP and AMP from ADP is also possible via 
ATP:AMP phosphotransferase (reviewed in Zimmermann, 1996). On the other hand, the 
majority of adenosine is generated by a single family of enzyme, 5’-nucleotidases, with the best 
classified being the ecto-5’-nucleotidase which is responsible for the degradation of AMP in the 
interstitial space. Extracellularly, ecto-5’-nucleotidase exhibit an affinity to AMP in the µM 
concentration. Intracellularly, 5’-nucleotidases has a high Km for AMP in the mM range with 
subsequent bi-directional transport of adenosine across the membrane (Zimmermann, 1996; 
Zimmermann & Braun, 1996; Latini & Pedata, 2001). Lastly, it is important to note that 
intracellular production of adenosine is also possible from hydrolysis of S-
adenosylhomocysteine, however, unlike production via AMP, this pathway is not linked to the 
energy state of the cell and does not appear to produce significantly in the brain (Pak et al., 1994; 
Latini et al., 1996). Furthermore, it appears that ecto-5’-nucleotidase is mainly expressed, via 
immunocytochemincal analysis, on the membranes of astrocytes, oligodendrocytes, and 
microglia (Schoen et al., 1987; Grondal et al., 1988) suggesting an important role of adenosine in 
immune response. Interestingly, it is also important to note that ecto-5’-nucleotidase is also 
expressed on neurons exclusively in the rodent hippocampus (Zimmermann, 1996; Zimmermann 
& Braun, 1996;; Schoen et al., 1999), presumably acting as a regulatory signal for excitability 
(Boison, 2007; Dunwiddie & Masino, 2001, Dunwiddie et al., 1997). Taken together, the data 
suggests that extracellular ATP is quickly broken down to adenosine as a possible immune 
regulator and a counter-regulation for excitotoxicity in the hippocampus.  
 The irreversible deamination of adenosine to inosine in the interstitial space is catalyzed 
by adenosine deaminase (ADA). In humans, polymorphism leading to reduced expression of 
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adenosine deaminase is the cause of a form of severe combined immunodeficiency (ADA-SCID) 
(Sanchez et al., 2007). Symptoms of ADA-SCID include chronic inflammatory diseases 
(Blackburn & Kellems, 2005) and toxicity to T and B cells (Kantoff et al., 1986) further 
suggesting the importance of adenosine in regulating immune responses.  
 
Adenosine signaling 
 Adenosine signals via four membrane bound G protein-coupled adenosine receptors 
(AR), divided into A1, A2A, A2B, and A3 subclasses of the P1 purine receptor family 
(Fredholm et al., 2001). All AR recognize extracellular adenosine and are antagonized by 
caffeine (Fredholm et al., 1999). Adenosine exerts its effects by regulating cAMP concentration. 
At physiological, sub-µM concentrations, the A1 receptor decreases intracellular cAMP via the 
Gi inhibition of adenylyl cyclase. Similar to the A1 receptor, the A3 receptor is also coupled to 
Gi to decrease cAMP concentration (Fig.1.1). However, it is in a relatively low abundance and 
appears to have minimal role in the brain (Rebola et al., 2005). During pathological states where 
extracellular adenosine concentration rise above µM range, the A2A receptor activates adenylyl 
cyclase to increase intracellular cAMP (Calker et al., 1979). Another receptor in the subclass of 
A2 receptor, the A2B receptor can also stimulate adenylyl cyclase at a much lower affinity to 
adenosine than A2A (Hide et al., 1992; Liang & Haltiwanger, 1995). 
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Adenosine in diseases 
 Being the backbone of both ATP and cAMP, adenosine is tied to the metabolic state of a 
cell. An increase in extracellular adenosine concentration is seen when energy expenditure is 
increased (Porkka-Heiskanen & Kalinchuk, 2010). Similarly, adenosine can also regulate various 
metabolic pathways including glucose metabolism (Nemeth et al., 2007; Dong et al., 2008) and 
inflammatory responses (Blackburn, 2003). Streptozotocin-induced hyperglycemia, a model of 
type-1 diabetes, is attenuated by A1 but not A2A AR agonism (Nemeth et al., 2007), where 
overexpression of A1AR in mice appears to protect mice from diet-induced insulin resistance 
(Dong et al., 2008) and activation of the A1 receptor inhibits lypolysis via inhibition of adenylyl 
cyclase (Dhalla et al., 2009). Conversely, the activation of adenylyl cyclase via A2A stimulation 
appears to promote glycogenolysis (Magistretti et al., 1986). Taken together, it appears that 
inhibition of adenylyl cyclase via adenosine signaling appears to promote insulin signaling. 
Furthermore, it appears that adenosine levels elevate in response to obesity (Kaartinen et al, 
1991) with a paralleled increase in circulating insulin levels (Xu et al., 2003), further suggesting 
a link between adenosine and insulin signaling. Indeed, inhibition of adenylyl cyclase adenosine 
potentiates insulin-induced activation of PI3K. Lastly, it is important to note that the diabetic-
like state enhances adenosine-evoked inhibition of hippocampal neurons (Morrison et al., 1992).  
 
Cognition 
 The physiological activation of the A1AR during high energy consumption is thought to 
decrease neuronal function by hyperpolarizing neurons and prevent neurotransmitter release, 
mainly glutamate, dopamine, serotonin, and acetylcholine (Boison, 2007; Cunha, 2005; Porkka-
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Heiskanen & Kalinchuk, 2011). Extracellular adenosine concentration is shown to increase 
during neuronal firing and is co-released with certain neurotransmitters (Dulla & Masino, 2013). 
It is suggested that the ability of adenosine to downregulate the brain during intense energy 
expenditure is an auto-protective role to minimize cell damage, while the diurnal fluctuation of 
adenosine concentration suggests that it may also have a role in regulating sleep and wakefulness 
(Porkka-Heiskanen & Kalinchuk, 2010; Porkka-Heiskanen, 1997, Huston et al., 1996). A rise in 
extracellular adenosine, however, has been linked to pathological conditions via the A2AAR, 
where inhibitors of the receptor have been shown to be neuroprotective (Cunha, 2005). It is 
important to note that both the A1 and A2A receptors can form complexes with neurotransmitter 
receptors to exert further regulation on neuronal transmission (Cunha, 2005). Table 1 
summarizes a partial list of the known interactions between adenosine and certain neurological 
diseases (Boison, 2008).  
 
Conclusion 
 The studies summarized in this review support the hypothesis that a dichotomous 
relationship exists between physiological and pathological adenosine receptor signaling. The 
normal functions of adenosine via A1 receptors appear to regulate sleep and wakefulness (Portas 
et al., 1997). As a signal or cellular energy balance, adenosine can be released in response to 
neuronal firing (Dulla & Masino, 2013) as a means to silence neurons. A similar mechanism 
exists to prevent overstimulation in neurological diseases such as in epilepsy, ischemia, or 
schizophrenia (Boison, 2006).  Therefore, A1-specific agonism may be beneficial in treating 
overactivity in the brain. However, when extracellular adenosine concentration reaches µM 
7 
 
levels, such as in pathological states of hypoxia or infection, the activation of the A2A receptor 
appears to elicit detrimental effects (Abbrachio & Cattabeni, 2006; Fredholm, 2010). Inhibition 
of the A2A receptor appears to be beneficial in prolonged diseases such as Alzheimer’s and 
Parkinson’s diseases (Dall’Ihna et al., 2003; Jacobson & Gao, 2006). This may be relevant in 
disease prevention when introducing the ubiquitous AR inhibitor, caffeine, to regular therapy 
(Fredholm, 2010; Rosso et al., 2008; Ascherio et al., 2001). Due to the opposing forces on 
adenylyl cyclase and cAMP, it appears that the bolstering of A1 signaling and the blocking of 
A2A signaling may confer synergistic benefits in neurological disorders (Gomes et al., 2011). In 
summary, the current research shows that augmented adenosine signaling appears to be involved 
in many neurological diseases. Therefore, specific, targeted agonism and antagonism of 
adenosine receptors may be novel and emerging targets.  
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CHAPTER 2: HYPOXIA/REOXYGENATION IMPAIRS MEMORY FORMATION VIA 
ADENOSINE-DEPENDENT ACTIVATION OF CASPASE-11 
 
Abstract 
 After hypoxia, a critical adverse outcome is the inability to create new memories. How 
anterograde amnesia develops or resolves remains elusive, but a link to brain-based IL-1 is 
suggested due to the vital role of IL-1 in both learning and brain injury. We examined memory 
formation in mice exposed to acute hypoxia. After reoxygenation, memory recall recovered 
faster than memory formation impacting novel object recognition and cued fear conditioning but 
not spatially cued Y-maze performance. The ability of mice to form new memories after 
hypoxia/reoxygenation was accelerated in IL-1 receptor 1 knockout (IL-1R1 KO) mice, in mice 
receiving IL-1 receptor antagonist (IL-1RA) and in mice given the caspase 1 inhibitor, Ac-
YVAD-CMK. Mechanistically, hypoxia/reoxygenation more than doubled caspase 1 activity in 
the brain which was localized to the amygdala compared to the hippocampus. This 
reoxygenation-dependent activation of caspase 1 was prevented by broad-spectrum adenosine 
receptor (AR) antagonism with caffeine and by targeted A1/A2A AR antagonism with 8-
cyclopentyl-1, 3-dipropylxanthine + 3, 7-dimethyl-1-propargylxanthine. Additionally, perfusion 
of adenosine activated caspase 1 in the brain while caffeine blocked this action by adenosine. 
Finally, resolution of anterograde amnesia was improved by both caffeine and by targeted 
A1/A2A AR antagonism. These findings indicate that amygdala-based anterograde amnesia after 
                                                          
1 This chapter appeared in its entirety in the Journal of Neuroscience and is referred to later in 
this dissertation as “Chiu et al., 2012”. Chiu, G. S., Chatterjee, D., Darmody, P. T., Walsh, J. P., 
Meling, D. D., Johnson, R. W., Freund, G. G. (2012). Hypoxia/Reoxygenation Impairs Memory 
Formation via Adenosine-Dependent Activation of Caspase 1. J. Neurosci. 32: 13945-13955. 
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hypoxia/reoxygenation is sustained by IL-1 generated through adenosine-dependent activation 
of caspase 1 after reoxygenation. 
 
Introduction 
 Injury to the brain through loss of oxygen triggers memory loss and causes learning 
deficiencies (Shukitt-Hale et al., 1996) including anterograde amnesia (Beatty et al., 1987). 
Importantly, acute hypoxia activates the neuroimmune system especially its IL-1 arm (Johnson et 
al., 2007). Brain-based IL-1 regulates cognitive function (Dantzer et al., 2008) and excess IL-1 in 
the brain is congruous with memory loss and impaired learning (Pugh et al., 2001). While 
neuroimmune system-generated IL-1 can cause brain injury (Ma et al., 2003), the mechanism by 
which IL-1 is produced in the brain during reduced oxygen conditions is not understood. IL-1 
and IL-1 are both present in the brain and each is implicated in complications related to hypoxia 
and ischemia (Touzani et al., 1999). Previously, we demonstrated that delayed recovery from 
acute hypoxia, as measured by social withdrawal in mice, was reliant on IL-1 because 
inhibition of the inflammatory caspase, caspase 1, dramatically shortened recuperation time 
(Johnson et al., 2007). As a member of the cysteine-aspartic acid protease family, caspase 1 
exists intracellularly as an inactive proenzyme (Damiano et al., 2004) until it is proteolytically 
processed by Nod-like receptor (NLR)-containing multi-protein inflammasomes (Miao et al., 
2011). Activated caspase 1 enzymatically processes pro-IL-1β to a secretable mature form 
(Bauernfeind et al., 2009). Inflammasome activation is elicited by a variety of microbe- and host-
associated bioactives (Schroder et al., 2010) including endogenous danger signals generated 
during reoxygenation like reactive oxygen species (ROS) (Tschopp et al., 2010), uric acid 
(Lamkanfi et al., 2007) and ATP (Di Virgilio, 2007).    
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 The restoration of oxygen after hypoxia is required for recovery but can, itself, cause 
tissue damage (González-Correa et al., 2007). Reoxygenation is frequently described in 
conjunction with reperfusion as occurs in ischemic injuries like myocardial infarction (Galaris et 
al., 1989) and stroke (Kostulas et al., 1999). Recently, reoxygenation unassociated with 
reperfusion has been linked to neural injury and cognitive dysfunction associated with sleep 
apnea (Gozal et al., 2001). Hypoxia/reoxygenation can precipitate endoplasmic reticulum (ER) 
stress (Bi et al., 2005), cell death (Saikumar et al., 1998) and inflammation (Johnson et al., 2007) 
but the means by which hypoxia/reoxygenation triggers these squelae is not clear. Currently, 
hypoxia/reoxygenation-dependent generation of ROS is a favored causative to reoxygenation 
injury (Li et al., 2002) but membrane destabilization is also a consequence of 
hypoxia/reoxygenation (Bickler et al., 1994; Calabresi et al., 1995). Importantly, membrane 
damage causes increases in extracellular concentrations of ATP, ADP and adenosine (Guinzberg 
et al., 2006).  
 
 Intracellular adenosine concentrations rapidly increase during states of negative energy 
balance when ATP hydrolysis outstrips ATP synthesis (Bruns, 1991; Fredholm et al., 1999). In 
contrast, extracellular adenosine is primarily derived from enzymatic phosphohydrolysis of ATP 
in the interstitial space (Hart et al., 2008). During hypoxia and ischemia, the extracellular 
concentration of adenosine can increase from 30-300 nM (Rudolphi et al., 1997) to 10-50 µM 
(Hagberg et al., 1987). In addition, extracellular AMP derived from intracellular ATP and ADP 
can be phosphohydrolyzed by CD73 to adenosine (Kobie et al., 2006). G protein-coupled 
adenosine receptors (ARs), which are divided into the subclasses A1, A2A, A2B and A3, all 
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recognize extracellular adenosine (Fredholm et al., 2001) and are blocked by the non-selective 
lipophilic competitive antagonist and nutraceutical, caffeine (Fredholm et al., 1999), as well as 
specific pharmacologic inhibitors. Therefore, in this study we sought to show that memory 
formation after acute hypoxia is adversely impacted by brain IL-1 through a mechanism reliant 
on AR-dependent activation of caspase 1. 
 
Methods 
 Materials- All reagents and chemicals were purchased from Sigma-Aldrich (St Louis, 
MO) except as noted. All primers were purchased from Applied Biosystems (Foster City, CA). 
 
 Animals- Animal use was conducted in accordance with Institutional Animal Care and 
Use Committee approved protocols at the University of Illinois. C57BL/6J male animals were 
purchased from Jackson Laboratory (Bar Harbor, ME) at 7 weeks of age. C57BL/6J IL-1R1 
knock-out (IL-1R1 KO) mice were bred in-house. Mice were group housed (×8 cage) in standard 
shoebox cages (length 46.9 cm; width 25.4 cm; height 12.5 cm) and allowed water and food ad 
libitum. Housing temperature (72 °F) and humidity (45–55%) were controlled as was a 12/12 h 
reversed dark-light cycle (2200–1000 h). Video recording of animal behavior was performed 
under red light using a Night Shot capable video camera (Sony HDR-XR500V). Except for 
locomotor activity which was performed as a repeated measure, all treatments at all time points 
represent separate cohorts of mice. The total number of mice utilized was 630. 
 
 ICV cannulation- As we have previously described (Johnson et al., 2007), mice were 
anesthetized IP with a sodium ketamine hydrochloride/xylazine hydrochloride solution 
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delivering 80 mg/kg ketamine and 12 mg/kg xylazine. Animals were placed in a Kopf stereotaxic 
instrument (David Kopf Instruments, Tujunga, CA) and mouse-specific brain infusion cannulas 
(Plastics One, Roanoke, Va) placed using the coordinates 0.6 mm posterior, 1.5 mm lateral to the 
bregma and 2.5 mm ventral from the surface of the skull. Cannulas were fixed to the skull with 
cyanoacrylate gel adhesive (Plastics One) and protected by a plastic guard. Mice were allowed 7 
days to recover.  
 
 Hypoxia/Reoxygenation- As we have previously described (Sherry et al., 2009), mice (n 
= 16/episode) were transferred from their home cages to a BioSperix ProOx/A-Chamber 
Biological Atmosphere System (Biospherix, Lacona NY) and subjected to either a 6% oxygen + 
94% nitrogen environment (hypoxia) or an atmospheric air environment (normoxia) for 2 h. 
After exposure mice were returned to their home cages.  
 
 Injectables- As we have previously described (Johnson et al., 2007), the caspase 1 
inhibitor, Ac-YVAD-CMK, (Bachem, Torrance, CA) was administered ICV at a dose of 50 
ng/uL/mouse immediately prior to hypoxia. Kineret (recombinant IL-1 RA) (AmGen, Thousand 
Oaks, CA) was administered IP at a dose of 1.4 mg/kg/mouse 30 min prior to hypoxia. CafCit 
(caffeine citrate) (Bedford Laboratories, Bedford, OH) was administered IP at a dose of 100 
mg/kg/mouse immediately prior to hypoxia. 8-cyclopentyl-1, 3-dipropylxanthine (A1 AR 
antagonist, 2.5 mg/kg/mouse) + 3, 7-dimethyl-1-propargylxanthine (A2A AR antagonist, 2.5 
mg/kg/mouse) (Chen et al., 2001) were administered as an IP cocktail 1 hour prior to hypoxia. 
N-Acetyl Cysteine (NAC) (Hospira, Inc., Lake Forest, IL) was administered IP at a dose of 50 
mg/kg/mouse immediately prior to hypoxia. For all studies, vehicle/control injection was 
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phosphate buffered saline (PBS) or normal saline (saline), as indicated, except for targeted AR 
inhibition which was 1:5 DMSO/castor oil.   
 
 Novel object recognition- Novel object recognition was performed as we have previously 
described (Lavin et al, 2011, York et al., 2011). In studies examining retrograde amnesia, mice 
(1 h prior to hypoxia) were individually transferred from their home cage to a home cage-sized 
memory arena containing two identical objects placed 10 cm apart at the short-side wall end for 
5 min (training). Mice were then subjected to hypoxia or normoxia. At the time points indicated 
post-hypoxia, mice (individually) were transferred back to the memory arena now containing one 
familiar object and one unfamiliar object (novel object) (testing). Investigative behavior of the 
objects was video recorded for 5 min and evaluated using EthoVision XT 7 (Noldus Information 
Technology) video tracking software. Percent investigation was calculated by dividing the time 
spent examining each object by the total time spent investigating both objects. In studies 
examining anterograde amnesia, mice were transferred for training at the time points indicated 
post hypoxia. Mice were then returned to their home cage for 55 min. As above, testing was 
initiated by returning mice to the memory arena with one familiar object and one novel object. 
Investigative behavior of the objects and time spent examining each object was performed as 
above.  
 
 Locomotion- Spontaneous locomotor activity was measured as we have previously 
described (Lavin et al., 2011, York et al., 2012). At the times indicated, mice were video 
recorded in their home cage for 5 min. Distance moved was quantified using EthoVision XT 7.  
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Cued fear conditioning- Cued fear conditioning was performed as we have previously 
described (York et al., 2011). 4 h post hypoxia, mice were placed in a Lafayette Instruments 
Cued and Contextual Fear Test Chamber (Lafayette Instruments, Lafayette IN). After a 30 sec 
acclamation period, mice were exposed to a white light (~23000 lux) for 2 sec, followed by a 2 
sec foot shock (60 V, 1 mA). After a 30 sec wait, mice were re-exposed to the light + foot shock 
cycle as above (training). Mice were then returned to their home cage. At the time points 
indicated, mice were reintroduced to the testing apparatus and allowed to acclimate for 30 sec. 
Mice then underwent two cycles of light without foot shock similar in parameters to the above 
(testing). All freezing behavior was evaluated via an integrated infrared photo beam array. Data 
were analyzed using the MotorMonitor Host Software (Lafayette Instruments). 
 
 Alternation- Spatially cued spontaneous alternations was performed as we have 
previously described (Lavin et al, 2011, York et al., 2011). In brief, mice were placed in a 
symmetrical 3-arm, clear Plexiglas Y-maze (40 cm length x 9 cm width x 16 cm height per arm 
with an arm angle of 120⁰) with side walls decorated with black triangles, black circles or black 
diagonal lines. Mice were randomly placed in one of the arms. Movement was recorded for 5 
min and mouse exploration evaluated from the video record. Mice were tested at 4, 52 and 76 
hours after hypoxia. Results are presented as the ratio of perfect alternations to total arm 
entrances. Perfect alternations were defined as exploration of two novel arms sequentially prior 
to a return to the start arm independent of a right or left arm choice at initiation. To have entered 
an arm, the mouse was required to have all four legs in that arm. 
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 Quantitative PCR (qPCR)- As we have previously described (York et al., 2012), RNA 
was isolated from the hippocampus dissected from PBS perfused whole brains. RNA was reverse 
transcribed using the High-Capacity cDNA Reverse Transcription Kit (PN 4368813) (Applied 
Biosystems). The TaqMan Gene Expression primers used were: Glial fibrillary acidic protein 
(GFAP) (Mm01253033_m1), aquaporin 4 (Mm000802131_m1), CD11b (Mm00434455_m1), 
F4/80 (Mm00802529_m1) and the peripheral benzodiazepine receptor (PBR) 
(Mm00437828_m1). qPCR was performed on a 7900 HT Fast Real-Time PCR System (Applied 
Biosystems) using TaqMan Universal PCR Master Mix (Applied Biosystems). To compare gene 
expression, a parallel amplification of endogenous RPS3 (Mm00656272_m1) was performed. 
Reactions with no reverse transcription and no template were included as negative controls. 
Relative quantitative evaluation of target gene to RPS3 was performed by comparing ΔCts, 
where Ct is the threshold concentration. 
 
 Caspase 1 activity- PBS perfused whole brains, brain regions (as indicated) and livers 
were frozen in liquid nitrogen then freeze fractured in reaction buffer containing 50 mM NaCl 
(Fisher Scientific, Fair Lawn, NJ), 10% glycerol, 1 mM DTT, 1 mM EDTA, 1 mM bestatin, 1 
mM pepstatin (EMD4Bioscience, Darmstadt, Germany), 1 mM 4-(2-aminoethyl)benzenesulfonyl 
fluoride hydrochloride and 50 mM HEPES, pH 7.4 (USB Corporation, Cleveland, OH) using the 
TissueLyser II (Qiagen, Valencia, CA) at a rotational frequency of 30/sec for 2 min. Lysates 
were clarified at 16,000 x g for 15 min at 4º C and the supernatant protein concentrations 
determined using the DC Protein Assay (Bio-Rad, Hercules, CA) and a ELx800 Absorbance 
Microplate Reader (BioTek Instrument, Winooski, VT). Supernatant protein concentrations were 
normalized to 10 mg/ml (whole brain and liver) or 2.5 mg/ml (brain regions) with reaction 
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buffer. Caspase 1 activity was determined colorimetrically in the clarified lysates using the 
caspase 1 substrate Ac-YVAD-p-nitroaniline (p-NA) (Enzo Life Science, Farmingdale, NY) at a 
final concentration of 4 mM. Substrate incubation was at 37º C for the times indicated. Moles of 
p-NA liberated was determined by a standard curve ranging from 0.075 mM to 0.3 mM p-NA 
(Enzo Life Science, Farmingdale, NY). Caspase 1 activity was calculated as (Δ[p-NA]/Δ 
time)/(total protein). 
  
Adenosine perfusion- Mice were euthanized via CO2 asphyxiation and the heart 
immediately exposed using straight 11.5 cm scissors (FST, Foster City, CA). The left ventricle 
was pieced with a 23 gage 1.25 inch needle (BD, Franklin Lakes, NJ) attached to a BD 30 mL 
syringe. Mice were perfused (as indicated) with 10, 30, 50 or 100 M adenosine, 500 µM NAC, 
500 M caffeine, 50 µM adenosine + 500 µM caffeine or 50 µM adenosine + 500 µM NAC in 
PBS, pH of 7.4 or PBS, pH 7.4 alone. 
 
 Glutathione (GSH)- Similar to methods we have previously described (Godbout et al., 
2002), GSH and glutathione disulfide (GSSG) were measured using the Glutathione Assay Kit 
(Sigma-Aldrich). As above, PBS perfused whole brains were frozen in liquid nitrogen then 
freeze fractured in the kit provided Assay Buffer using the TissueLyser II. After brain 
homogenization, GSH/GSSG was quantified spectrophotometrically following the instructions of 
the manufacturer and a ELx800Absorbance Microplate Reader 
 
 Phospho (p)-ERK 1/2, p-p38 MAPK and p-JNK- Similar to methods we have previously 
described (Sherry et al., 2007), whole brains were frozen in liquid nitrogen then freeze fractured, 
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as above, in a homogenization buffer containing 50 mM NaCl, 10% glycerol, 1 mM DTT, 2 mM 
sodium orthovanadate, 250 nM okadaic acid, 1:200 Protease Inhibitor Cocktail III (Calbiochem, 
Darmstadt, Germany) and 50 mM HEPES, pH 7.4 using the TissueLyser II. Lysates were 
clarified at 16,000 x g for 15 min at 4º C and the supernatant protein concentrations determined 
using the DC Protein Assay, as above. p-ERK 12/, p-p38 MAPK and p-JNK were measured in 
50 L of lysate using a Bio-Plex phosphoprotein assay (Bio-Rad, Hercules, CA) and Luminex 
100 System (Luminex, Austin, TX) following the instructions of the manufacturer. Results are 
expressed relative change in phosphorylation/total protein. 
 
 Immunohistochemistry- Similar to methods we have previously described (Johnson et al., 
2007, Davis-Devine et al., 2003), mice were perfused with ice-cold 10% neutral buffered 
formalin. Brains were removed and using a Mouse Brain Slicer (Zivic Instruments, Pittsburgh, 
PA) coronal sections ranging from the bregma to -3.0 mm from the bregma where generated. 
These slices were fixed in 10% neutral buffered formalin for 24 hr then paraffin embedded and 
sectioned. A 4 m section at -1.7 mm from the bregma was immunostained for GFAP using a 
rabbit anti-GFAP antibody (DAKO, Carpinteria, CA) at a dilution of 1:2000 at RT for 30 min. 
Detection was performed using the Rabbit Link/SS Label detection kit (Biogenex, San Ramon, 
CA) in conjunction with the Biogenex i6000 Automated Staining System (incubation time was 
15 min). After coverslipping, the entire slide was imaged at 40x with a NanoZoomer 2.0-HT 
(Hamamatsu, Bridgewater, NJ). 
 
 Uric Acid- Blood was collected via cardiac puncture using a 26G x 3/8 inch needle 
(Becton Dickinson, Franklin Lakes, NJ) and allowed to stand at room temperature for 30 min. 
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Serum was generated  by centrifuging samples at 10,000 x g for 15 min. Serum uric acid was 
determined on a AU680 analyzer (Beckman Coulter, Brea CA).  
 
 Statistics- All data are presented as mean ± SEM. Data were analyzed using Sigma Plot 
11.2 (Systat Software, Chicago, IL). To test for statistical differences, a one-way or two-way 
ANOVA was used with or without repeated measurements where needed. Tukey’s test was used 
for post-hoc pair-wise multiple comparison procedures. Where indicated, raw data was 
transformed using a log10 transformation to attain equal variance. All statistical analysis 
included testing for time point x treatment interactions. Statistical significance was denoted as p 
< 0.05. 
 
Results 
 Restoration of memory recall after acute hypoxia- Fig.2.1A demonstrates that if memory 
formation (training) occurred 1 h prior to hypoxia, the ability of mice to recall that memory in 
the testing phase was restored after 4 h of reoxygenation (82.5 ± 2.1% vs 81.3 ± 2.1%, normoxia 
vs hypoxia). Immediately after hypoxia mice did not explore either a familiar or novel object. 
After 1, 2 and 3 h of reoxygenation mice explored a novel object as if it were a familiar object 
(51.8 ± 5.7%, 61.6 ± 6.2% and 72.6 ± 3.6%, respectively). Main effects of hypoxia (p < 0.001) 
and time (p < 0.001); 0 h time point: p < 0.001, normoxic v hypoxic (82.5 ± 1.9% v 0 ± 0%); 1 h 
time point: p < 0.001, normoxic v hypoxic (79.2 ± 1.6% v 51.8 ± 5.7%); 2 h time point: p < 
0.001, normoxic v hypoxic (81.9 ± 2.1% v 61.6 ± 6.2%); 3 h time point: p < 0.05, normoxic v 
hypoxic (84.5 ± 2.4% v 72.6 ± 3.6%). After 4, 5 and 6 h of reoxygenation mice preferably 
explored the novel object over the familiar (81.3% vs 18.7%, 77.5% vs 22.5% and 75.7% vs 
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24.3%, respectively). Fig.2.1B shows that hypoxic mouse spontaneous locomotor activity was 
comparable to that of normoxic mice after 2 hrs of reoxygenation. Main effects of hypoxia (p < 
0.05) and time (p < 0.05); 0 h time point: p < 0.001, normoxic v hypoxic (1910.4 ± 128.9 cm v 
314.7 ± 159.1 cm); 1 h time point: p < 0.05, normoxic v hypoxic (1772.5 ± 128.5 cm v 1297.7 ± 
115.3 cm). 
 
 Memory formation recovers more slowly than memory recall after acute hypoxia- 
Fig.2.2A illustrates that if memory formation occurred after hypoxia (training) the ability of mice 
to learn does not recover until 6 h of reoxygenation (66.2 ± 1.0% vs 76.3 ± 1.8%). At 3, 4 and 5 
h of reoxygenation, mice exposed to hypoxia explored a novel object 54.3 ± 0.8%, 57.0 ± 2.4% 
and 55.9 ± 1.5%, respectively. Main effects of groups (p < 0.001).; normoxic v 3 h time point: p 
< 0.001 (75.3 ± 1.9% v 54.3 ± 0.8%), normoxic v 4 h time point: p < 0.001 (75.3 ± 1.9% v 57.0 
± 2.47%), normoxic v 5 h time point: p < 0.001 (75.3 ± 1.9% v 55.9 ± 1.5%). Data was 
transformed. Fig.2.2B confirms that memory formation after hypoxia is impaired. In the cued 
fear conditioning test, both normoxic and hypoxic mice (after 4 hrs of reoxygenation) had similar 
immobility when first exposed to cue/foot shock (training). When retested with just the cue 
(testing), after 5 and 52 hrs of reoxygenation, normoxic mice demonstrated a 121.9% and 
123.8% increase in immobility, respectively, when compared to the initial cue/foot shock 
exposure (training). In contrast, hypoxic mice when retested with just the cue at 5 and 52 hrs of 
reoxygenation showed immobility comparable to the initial cue/foot shock exposure (training). 
Main effects of hypoxia (p < 0.001) and time (p < 0.05); 4 h time point: p < 0.659, normoxic v 
hypoxic (83.0 ± 3.7 sec v 80.7 ± 4.4 sec); 5 h time point: p < 0.05, normoxic v hypoxic (101.1 ± 
3.3 sec v 84.8 ± 3.1 sec); 52 h time point: p < 0.05, normoxic v hypoxic (102.7 ± 3.3 sec v 86.2 ± 
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3.6 sec). Fig.2.2C shows that perfect alternations in a cued Y-maze were not affected by hypoxia 
at 4, 52, and 76 hours after reoxygenation. Main effects of hypoxia (p = 0.626) and time (p = 
0.235). 
 
Knockout of IL-1R1 improves memory formation and locomotion while blunting 
activation of ERK1/2 and p38 MAPK- Fig.2.3A demonstrates that if memory formation (training) 
occurred 4 hrs after hypoxia, IL-1R1 KO mice had accelerated recovery of memory formation. 
At 5 hrs of reoxygenation, hypoxic IL-1R1 KO mice explored a novel object similar to normoxic 
wild type (WT) mice (70.2 ±7.4% vs 63.5 ± 3.1%). Hypoxic WT mice explored a novel object as 
if it were a familiar object (47.9 ± 4.7%). Main effects of genotype (p < 0.05) and hypoxia (p = 
0.235); normoxic WT v hypoxic WT: p < 0.05 (63.5 ± 3.1% v 47.9 ± 4.7%), normoxic IL-1R1 
KO v hypoxic IL-1R1 KO: p = 0.645 (66.9 ± 3.3% v 70.2 ± 7.4%), hypoxic WT v hypoxic IL-
1R1 KO: p < 0.05 (47.9 ± 4.7% v 70.2 ± 7.4%). Similar results were seen in mice administered 
IL-1 RA (Fig.2.3B) (main effects of treatment (p < 0.05) and hypoxia (p = 0.055); saline 
normoxic v saline hypoxic: p < 0.05 (66.9 ± 5.3% v 53.2 ± 5.3%), IL-1RA normoxic v IL-1RA 
hypoxic: p = 0.457 (72.1 ± 3.4% v 67.2 ± 4.0%), saline hypoxic v IL-1RA hypoxic: p < 0.05 
(53.2 ± 5.3% v 67.2 ± 4.0%)) and in mice administered Ac-YVAD-CMK (Fig.2.3C) (main 
effects of treatment (p < 0.05) and hypoxia (p = 0.5); PBS normoxic v PBS hypoxic: p < 0.05 
(69.7 ± 3.5% v 55.7 ± 4.2%), Ac-YVAD normoxic v Ac-YVAD hypoxic: p = 0.157 (67.1 ± 
3.3% v 75.5 ± 5.0%), PBS hypoxic v Ac-YVAD hypoxic: p < 0.05 (55.7 ± 4.2% v 75.5 ± 
5.0%)). Fig.2.3D illustrated that spontaneous locomotor activity of IL-1R1 KO mice was 
restored after 1 hr of reoxygenation as opposed to 2 hrs in hypoxic WT mice. Main effects of 
hypoxia (p < 0.001), genotype (p = 0.781) and time (p = 0.193); 0 h time point: normoxic WT v 
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hypoxic WT: p < 0.001 (2202.2 ± 109.2 cm v 936.2 ± 267.6 cm); normoxic IL-1R1 KO v 
hypoxic IL-1R1 KO: p < 0.001 (2068.5 ± 40.0 cm v 535.0 ± 260.5 cm); normoxic WT v 
normoxic IL-1R1 KO: p = 0.695 (2202.2 ± 109.2 cm v 2068.5 ± 40.0 cm); hypoxic WT v 
hypoxic IL-1R1 KO: p = 0.165 (936.2 ± 267.6 cm v 535.0 ± 260.5 cm); 1 h time point: normoxic 
WT v hypoxic WT: p < 0.05 (1989.1 ± 132.5 cm v 1283.3 ± 132.1 cm); normoxic IL-1R1 KO v 
hypoxic IL-1R1 KO: p = 0.546 (1417.1 ± 223.1 cm v 1615.6 ± 140.1 cm) normoxic WT v 
normoxic IL-1R1 KO: p = 0.111 (1989.1 ± 132.5 cm v 1417.1 ± 223.1 cm); hypoxic WT v 
hypoxic IL-1R1 KO: p = 0.245 (1283.3 ± 132.1 cm v 1615.6 ± 140.1 cm). Fig.2.3E shows that 
after 1 hr of reoxygenation ERK1/2 (normoxic v hypoxic; 1.0 ± 0.2 fold v 1.4 ± 0.1 fold; p = 
0.05) and p38 MAPK (normoxic v hypoxic; 1.0 ± 0.2 fold v 1.5 ± 0.2 fold; p = 0.05) were 
activated in the brains of WT but not IL-1R1 KO mice (p = 0.94; p = 0.91, respectively). In 
contrast, JNK was not significantly activated in either WT or IL-1R1 KO 1 hr after 
reoxygenation. 
  
AR blockade prevents hypoxia-dependent activation of caspase 1 in the brain- Fig.2.4A 
shows that after 1 hr of reoxygenation, brain caspase 1 is 208.8% more active in hypoxic mice 
than normoxic mice. Hypoxic mice not allowed to significantly reoxygenate did not demonstrate 
an increase in brain caspase 1 activity. In addition, after 6 hrs of reoxygenation, brain caspase 1 
activity was similar to that of normoxic mice. 0 h time point: p = 0.525, normoxic v hypoxic (1.0 
± 0.1 fold v 1.1 ± 0.2 fold); 1 h time point: p < 0.001, normoxic v hypoxic (1.0 ± 0.2 fold v 2.1 ± 
0.2 fold); 6 h time point: p = 0.930, normoxic v hypoxic (1.0 ± 0.1 fold v 1.0 ± 0.1 fold). 
Figs.4B&C illustrate that mice pre-treated with either caffeine or an A1/A2A AR inhibitor 
cocktail did not up-regulate caspase 1 activity in the brain after 1 hr of reoxygenation (saline 
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hypoxic v caffeine hypoxic: p < 0.001 (2.6 ± 0.0 fold v 1.0 ± 0.2 fold); vehicle hypoxic v 
A1/A2A antag hypoxic: p < 0.05 (2.6 ± 0.3 fold v 1.5 ± 0.1 fold)). Table 1 demonstrates that 
after 1 hr of reoxygenation hypoxia lowers the brain GSH/GSSG ratio by 49% (p < 0.05) and 
that caffeine and NAC each prevented this decline. The GSH/GSSG ratio was unchanged if 
hypoxic mice were not afforded significant time to reoxygenate (1.00 ± 0.22 fold vs 1.02 ± 0.22 
fold, normoxia vs hypoxia; p = 0.832). Importantly, NAC pre-treated mice did not lose the 
ability to up-regulate brain caspase 1 activity after reoxygenation (Fig.2.4D). Main effects of 
treatment (p = 0.358) and hypoxia (p < 0.001); saline normoxic v saline hypoxic: p < 0.05 (1.0 ± 
0.0 fold v 2.1 ± 0.5 fold), NAC normoxic v NAC hypoxic: p < 0.05 (1.24 ± 0.2 fold v 2.2 ± 0.4 
fold), saline hypoxic v NAC hypoxic: p = 0.498 (2.1 ± 0.5 fold v 2.2 ± 0.4 fold). Fig.2.4E shows 
that mice perfused with 30, 50 and 100 M adenosine have a 167%, 225% and 247% increase in 
brain caspase 1 activity, respectively. PBS perfused v adenosine perfused. Main effect of 
treatment (p < 0.001). 0 µM v 10 µM: p = 0.844 (1.0 ± 0.1 v 0.8 ± 0.1), 0 µM v 30 µM: p < 0.05 
(1.0 ± 0.1 v 1.6 ± 0.2), 0 µM v 50 µM: p < 0.001(1.0 ± 0.1 v 2.3 ± 0.3), 0 µM v 100 µM: p < 
0.001(1.0 ± 0.1 v 2.5 ± 0.1), 10 µM v 30 µM: p = 0.01 (0.8 ± 0.1 v 1.6 ± 0.2), 10 µM v 50 µM: p 
< 0.001(0.8 ± 0.1 v 2.3 ± 0.3), 10 µM v 100 µM: p < 0.001(0.8 ± 0.1 v 2.5 ± 0.1), 30 µM v 50 
µM: p = 0.075 (1.6 ± 0.2 v 2.3 ± 0.3), 30 µM v 100 µM: p = 0.023 (1.6 ± 0.2 v 2.5 ± 0.1), 50 µM 
v 100 µM: p = 0.940 (2.3 ± 0.3 v 2.5 ± 0.1). Figs.4F&G demonstrate that caffeine but not NAC 
inhibits adenosine-dependent activation of caspase 1 when adenosine is perfused into mice 
(Fig.2.4F, main effect of treatment (p < 0.001). PBS v adenosine: p < 0.001 (1.0 ± 0.1 v 1.9 ± 
0.1), adenosine v caffeine: p < 0.001 (1.9 ± 0.1 v 0.9 ± 0.1), adenosine v adenosine + caffeine: p 
< 0.001 (1.9 ± 0.1 v 1.3 ± 0.1), adenosine + caffeine v caffeine: p = 0.06 (0.9 ± 0.1 v 1.3 ± 0.1), 
PBS v adenosine + caffeine: p = 0.267 (1.0 ± 0.1 v 1.3 ± 0.1), PBS v caffeine: p = 0.841 (1.0 ± 
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0.1 v 0.9 ± 0.1). Fig.2.4G, main effect of treatment (p < 0.05). PBS v adenosine: p < 0.05 (1.0 ± 
0.0 v 1.9 ± 0.1), adenosine v NAC: p < 0.05 (1.9 ± 0.1 v 1.2 ± 0.3), adenosine v adenosine + 
NAC: p = 0.991 (1.9 ± 0.1 v 1.8 ± 0.1), adenosine + NAC v NAC: p = 0.076 (1.8 ± 0.1 v 1.2 ± 
0.3), PBS v adenosine + NAC: p < 0.05 (1.0 ± 0.0 v 1.8 ± 0.1), PBS v NAC: p = 0.897 (1.0 ± 0.0 
v 1.2 ± 0.3)). Finally, to examine another potential activator of the inflammasome, uric acid was 
examined. After 1 hr of reoxygenation serum uric acid levels were similar in normoxic and 
hypoxic mice (3.3 ± 0.4 mg/dL vs 3. 1± 0.2 mg/dL). 
 
Hypoxia induces brain region-specific activation of caspase 1- Fig.2.5A shows that 1 hr 
after hypoxia/reoxygenation, caspase 1 activity in the amygdala compared to control was 
increased 180% (normoxic v hypoxic, 1.0 ± 0.1 v 1.8 ± 0.1, p < 0.001). Hippocampal caspase 1 
activity was not impacted by hypoxia/reoxygenation (normoxic v hypoxic: 1.0 ± 0.1 v 0.7 ± 0.1, 
p = 0.134) nor was pre-frontal cortex or cerebellar caspase 1 activity (data not shown). To 
determine if significant gliosis occurred after hypoxia, immunohistochemistry for GFAP was 
performed. Fig.2.5B demonstrates no change in GFAP expression at 1 and 6 hrs of 
reoxygenation in both WT and IL-1R1 KO mice. Additionally, qPCR for GFAP and aquaporin 4 
gene transcripts were examined in the amygdala and hippocampus at 1 and 6 hrs after 
reoxygenation in WT and IL-1R1 KO mice revealing no impact of hypoxia (data not shown). To 
examine microglia infiltration/proliferation/activation, gene transcripts for CD11b, F4/80 and 
PBR were examined in the amygdala and hippocampus after 1 and 6 hr of reoxygenation in WT 
and IL-1R1 KO mice. No differences were observed (data not shown). 
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AR blockade speeds recovery of memory formation after hypoxia- Fig.2.6A demonstrates 
that if memory formation (training) occurred 4 hrs after hypoxia, mice administered caffeine had 
accelerated recovery of memory formation. At 5 hrs of reoxygenation, hypoxic mice pre-treated 
with caffeine explored a novel object similar to normoxic mice (68.0 ± 3.6% vs 69.5 ± 5.6%). 
Hypoxic mice pre-administered vehicle explored a novel object as if it were a familiar object 
(48.6 ± 2.4%). Main effects of treatment (p < 0.05) and hypoxia (p < 0.05); saline normoxic v 
saline hypoxic: p < 0.05 (69.5 ± 5.6% v 48.6 ± 2.4%), caffeine normoxic v caffeine hypoxic: p = 
0.838 (69.2 ± 4.6% v 68.0 ± 3.6%), saline hypoxic v caffeine hypoxic: p < 0.05 (48.6 ± 2.4% v 
68.0 ± 3.6%). Fig.2.6B demonstrates that if memory formation (training) occurred 4 hrs after 
hypoxia, mice administered 8-cyclopentyl-1, 3-dipropylxanthine + 3, 7-dimethyl-1-
propargylxanthine had accelerated recovery of memory formation. At 5 hrs of reoxygenation, 
hypoxic mice pre-treated with 8-cyclopentyl-1, 3-dipropylxanthine + 3, 7-dimethyl-1-
propargylxanthine explored a novel object similar to normoxic mice (76.1 ± 3.7% vs 73.5 ± 
3.4%). Hypoxic mice pre-administered vehicle explored a novel object as if it were a familiar 
object (62.4 ± 3.2%). Main effects of treatment (p = 0.055) and hypoxia (p = 0.197), hypoxia x 
treatment (p < 0.05); vehicle normoxic v vehicle hypoxic: p < 0.05 (73.7 ± 2.7% v 62.4 ± 3.2%), 
8-cyclopentyl-1, 3-dipropylxanthine + 3, 7-dimethyl-1-propargylxanthine normoxic v 8-
cyclopentyl-1, 3-dipropylxanthine + 3, 7-dimethyl-1-propargylxanthine hypoxic: p = 0.583 (73.5 
± 3.4% v 76.1 ± 3.7%), vehicle hypoxic v 8-cyclopentyl-1, 3-dipropylxanthine + 3, 7-dimethyl-
1-propargylxanthine hypoxic: p < 0.05 (62.4 ± 3.2% v 76.1 ± 3.7%). 
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Discussion 
In humans, the causes of a confusional state are numerous and include drugs, toxins, 
infections, head injuries and metabolic derangements (Gascon & Barlow, 1970, Mori & 
Yamadori, 1987). Hypoxemia is a well-recognized antecedent to brain injury (Rees et al., 1998) 
that can precipitate memory loss well beyond hypoxemia-associated confusion or delirium 
(Berggren, 1987). In rodents, hypoxia has long been known to causes retrograde amnesia (Sara 
and Lefevre, 1972). The inability of rodents to recall a previously learned task or avoid noxious 
stimuli after hypoxia can be long-lived (24 h) as Sara et al show in rats exposed to 3.5% oxygen 
(Sara and Lefevre, 1972). In addition, this memory loss can occur without significant brain cell 
death because, in mice, as Kyff et al show (Kyff et al, 1989) and we confirm, 2 h of hypoxia 
above 5% oxygen does not lead to identifiable neuronal death even in the hippocampus (Johnson 
et al., 2007). Here we show that the acute hypoxia used induced minimal neuroinflammation 
over the 6 hrs examined as reflected by no change in the gene expression of GFAP, aquaporin 4, 
CD11b, F4/80 and PBR, and no change in GFAP protein expression. These findings indicate that 
unlike ischemia where all of the aforementioned astrocyte and microglial markers are rapidly up-
regulated (Feuerstein et al., 1997, Lu & Sun, 2003, Natale et al., 2003, Taguchi et al., 2007, 
Taniguchi et al., 2007, Xiong et al., 2009) and significant gliosis occurs, acute hypoxia can be a 
recoverable event that results in negligible neuropathology.  
 
The mechanism protecting burrowing mammals, especially certain moles which can 
survive severe oxygen deprivation (3%) for extended times (8 hrs) (Avivi, 2006), from acute 
hypoxia is not clear but its origin, evolutionarily, appears as a safeguard to burrow collapse. As 
Fig.2.1A shows, mice exposed to 6% hypoxia for 2 h developed retrograde amnesia that resolved 
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after 4 hrs of reoxygenation. This loss of memory was not solely due to a motor deficit that 
prevented mice from performing the task because mice had regained normal locomotor activity 
after 2 hrs of reoxygenation (Fig.2.1B).  
 
Post hypoxia, the ability of mice to form a new memory did not recover until after 6 h of 
reoxygenation (Fig.2.2A). Since the training phase for novel object recognition occurred 1 hr 
prior to the testing phase, memory formation after hypoxia was impaired within the first 5 hrs of 
reoxygenation. To determine if the results obtained were memory type specific, cued fear 
conditioning and spatially cued Y-maze performance were utilized as additional tests of memory 
dysfunction. Fig.2.2B illustrates that with cued fear conditioning mice failed to learn when 
trained after 4 hrs of reoxygenation and that this was a failure of memory formation and not a 
deficiency in task performance because even after 52 h of reoxygenation mice did not recall the 
learned cue. Unlike fear conditioning, mice performance in a spatially cued Y-maze was not 
impacted by hypoxia (Fig.2.2C) demonstrating spatial memory and hence the hippocampus may 
be less impacted by hypoxia.    
 
Although hypoxia appears tied to anterograde amnesia in humans (Beatty, 1987), almost 
no work has been performed in animal models. A single study by Udayabanu et al looked at 
retrograde and anterograde memory in a mouse model of acute hypobaric hypoxia with a 
calculated oxygen percentage of 7% (307.4 Torr) for 6 hrs (Udayabanu et al., 2008). They 
concluded that hypoxia only impacted retrograde memory and not anterograde memory. While 
they conducted memory formation 2 hrs post hypoxia, the tests they used (passive avoidance 
step-through and elevated plus maze) were strongly dependent on spatial memory and, thus, the 
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hippocampus (Yirmiya et al, 2002, Rodgers et al., 1997). Likewise, in our study, spatially cued Y 
maze performance was not affected by hypoxia while our more amygdala-dependent tests (object 
recognition and cued fear conditioning) were (Moses et al., 2005). Interestingly, Broadbent et al. 
showed that in rats spatial memory was impaired when 30-50% of the dorsal hippocampus or 
50% of the ventral hippocampus is damaged. Object recognition memory, however, was only 
impaired after 75-100% of the dorsal hippocampus is injured (Broadbent et al., 2004). Taken 
together these findings indicate that acute hypoxia impairs memory that is predominantly 
decoupled from the hippocampus. Support for this contention is seen in Fig.2.5A which 
illustrates that hypoxia/reoxygenation increases caspase 1 activation in the amygdala but not in 
the hippocampus.  
 
Brain IL-1 is important to the recovery of memory formation after hypoxia. Fig.2.3C 
shows that the caspase 1 specific inhibitor YVAD-CMK (Wu et al., 2010) administered ICV 
speeds the recovery of memory formation after hypoxia. Since caspase 1 can process other 
proteins besides pro-IL-1 (Keller et al., 2008), we confirmed these findings by administering 
IL-1 RA (Fig.2.3B) and by using IL-1R1 KO mice (Fig 3A). Since YVAD-CMK was 
administered ICV, our results indicate that brain generated IL-1 is responsible for impairing 
memory formation after hypoxia as opposed to IL-1 from the peripheral blood. That a 
dysregulation in brain IL-1 negatively impacts certain aspects of memory is not surprising. IL-1 
is best known for its role in hippocampal-dependent memory (Goshen et al., 2007) and 
conditions that disrupt IL-1 signaling impair mouse water maze and passive avoidance 
performance (Yirmiya et al., 2002). As proposed by Goshen and Yirmiya, hippocampal-
dependent memory and plasticity are regulated by IL-1 in an inverted U shaped correlation 
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where low and high brain IL-1 signaling have similar impacts (Yirmiya et al., 2002). As for the 
role of IL-1 in novel object recognition, little is known. Costello et al just demonstrated that mice 
deficient in the single-Ig-interleukin-1 related receptor have impaired novel object recognition as 
well as an up-regulation of IL-1 but not IL-1 in the brain (Costello et al., 2011). They propose 
that IL-1 via IL-1R1 may drive certain memory impairments especially as related to infectious 
etiologies. Fig.2.5E shows that in hypoxia activation of ERK1/2 and p38 MAPK may be 
important to IL-1 regulated memory because 1 hr after reoxygenation these kinases had reduced 
ser/thr phosphorylation in IL-1R1 KO mice when compared to wild type mice. Thus, our results 
suggest that IL-1 may be more important in disease states involving low-oxygen and that 
MAPK superfamily members downstream of IL-1R1 may be regulatory.  
 
As we and others have shown, brain IL-1 is elicited during activation of the 
neuroimmune system (Johnson et al., 2007, Dantzer et al., 2008, Kostulas et al., 1999). Basally, 
mature IL-1 is nearly undetectable in the rodent brain (Layé et al., 2000; Takao et al., 1993; 
Taupin et al., 1993) but with neuroimmune stimulation, especially ischemic injury, IL-1 is 
measurable (Saito et al., 1996) promoting brain injury (Rothwell, 2003). How mature IL-1 is 
generated in the brain is unknown. Peripherally, the inflammasome is critical to caspase 1 
activation and caspase 1 is responsible for the final enzymatic cleavage of pro-IL-1 to 
secretable IL-1 (Lamkanfi et al., 2007). Fig.2.4A demonstrates that there is increased brain 
caspase 1 activity after hypoxia but that reoxygenation is important to this activity because non-
reoxygenated mice do no show increased caspase 1 activity. Since reoxygenation appears 
necessary to brain caspase 1 activation, we examined known danger signals potentially relevant 
to peripheral inflammasome activation and to hypoxia. ROS are considered to play a role in 
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reoxygenation/reperfusion injury and redox-dependent activation of the NLRP3 inflammasome 
has recently been shown (Martinon, 2010; Tschopp & Schroder, 2010). Table 1 demonstrates 
that hypoxia/reoxygenation markedly reduced the GSH/GSSG ratio indicative of ROS 
generation. As expected, administration of the GSH precursor and antioxidant, NAC, (Raju et al., 
1994) prior to hypoxia prevented a hypoxia/reoxygenation-dependent decline in the GSH/GSSG 
ratio. Additionally caffeine which has been shown to have antioxidant properties (Devasagayam 
et al., 1996; Shi & Dalal, 1991) also prevented a decline in the GSH/GSSG ratio after 
hypoxia/reoxygenation. Unexpectedly, caffeine (Fig.2.4B) and more importantly antagonism of 
the A1+A2A ARs (Fig.2.4C) prevented reoxygenation-dependent activation of caspase 1 while 
NAC did not (Fig.2.4D). Furthermore, caffeine (Fig.2.6A) and A1/A2A AR antagonism 
(Fig.2.6B) but not NAC (data not shown) sped recovery from hypoxia-induced loss of memory 
formation. These findings indicate that adenosine triggers hypoxia/reperfusion dependent 
caspase 1 activation resulting in a delay in the ability to form new memories. To further confirm 
that adenosine activates caspase 1 in the brain, mice were perfused with adenosine. Fig.2.4E 
shows that in a dose dependent manner adenosine activates brain caspase 1 and that the EC50 of 
30 M is consistent with interstitial adenosine concentrations seen the microenvironment of 
hypoxic tissue (10-50 M) (Sitkovsky et al.. 2005). Fig.2.4F&G demonstrate that caffeine but 
NAC blocked adenosine-dependent activation of caspase 1 additional illustrating that ARs but 
not ROSs are important to adenosine-dependent caspase 1 activation.  
 
To date, neither adenosine nor its receptors are implicated as direct activators of the 
inflammasome or of caspase 1. However, AR antagonism, especially via caffeine, is linked to 
cognitive improvement in certain neurodegenerative diseases (Cunha et al., 2010) and as a 
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protectant against Alzheimer’s disease (Cao et al., 2012). How caffeine achieves this function is 
unclear but it has been postulated that since adenosine acts as an inhibitory neurotransmitter the 
ability of caffeine to suppress this effect of adenosine is beneficial (Chen et al., 2001). The 
antioxidant qualities of caffeine have been postulated as a mechanism but this theory does not 
explain the action of more specific AR antagonists which lack antioxidant properties (ref) and 
are shown to protect neurons against ischemic injury (Phillis, 1995). Therefore, caffeine acting as 
an inhibitor of IL-1 generation, as implicated here, is a potentially new mechanism for its 
action. 
 
How adenosine activates the inflammasome through ARs needs to be defined. Purines are 
metabolized to uric acid which is a well described activator of the inflammasome (Pétrilli & 
Martinon, 2007). We measured serum uric acid after hypoxia and saw no increase after 1 h of 
reoxygenation. This finding is consistent with others who have seen that xanthine oxidase which 
catalyzes the oxidation of hypoxanthine to xanthine and xanthine to uric acid is increased after 
reoxygenation but only at more distant time points (Cherubini et al., 2000; Gonzalez-Flecha & 
Cutrin, 1993; Jones et al., 1968; Poulsen et al., 1993). A potential mechanism by which ARs 
activate caspase 1 is through K+ flux. When triggered by high extracellular concentrations of 
K+, pannexin 1 channels induce activation of caspase 1 (Silverman et al., 2009). Hypoxia causes 
increased extracellular concentrations of K+ in brain slice cultures that can be inhibited by AR 
antagonism (Croning et al., 1995). Importantly, adenosine can stimulate cellular K+ release 
through the A1 and A2A ARs (Fredholm et al., 2001, Sanjani et al., 2011).  
 
31 
 
Finally, the brain is rich ARs and they are expressed on a wide range of brain-based cells 
including microglia (A1, A2A, and A3) (Sperlágh & Illes,2007), astrocytes (A1, A2A, A2B and 
A3), neurons (A1 and A2A) (Haskó et al., 2005) and endothelial cells (A2A and A3) (Fredholm 
et al., 2001; Platts, Duling, 2004). Thus, further work is needed to determine not only how 
adenosine activates caspase 1 but what are the particular brain cells most responsible for caspase 
1 activation and the production of mature IL-1 after hypoxia/reoxygenation. Currently, some 
specificity to the brain is evident because hypoxia/reoxygenation did not increase liver caspase 1 
activity (data not shown). Taken together, our results indicate that hypoxia/reoxygenation 
increases caspase 1 activity in the brain thereby impairing amygdala-based memory formation. 
These findings are important because they delineate a new mechanism linking adenosine to 
activation of the inflammasome. 
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CHAPTER 3: ADENOSINE THROUGH THE A2A ADENOSINE RECEPTOR 
INCREASES IL-1β IN THE BRAIN CONTRIBUTING TO ANXIETY 
 
Abstract 
 Anxiety is one of the most commonly reported psychiatric conditions, but its 
pathogenesis is poorly understood. Ailments associated with activation of the innate immune 
system, however, are increasingly linked to anxiety disorders. In adult male mice, we found that 
adenosine doubled caspase-1 activity in brain by a pathway reliant on ATP-sensitive potassium 
(KATP) channels, protein kinase A (PKA) and the A2A adenosine receptor (AR). In addition, 
adenosine-dependent activation of caspase-1 increased interleukin (IL)-1 in the brain by two-
fold. Peripheral administration of adenosine in wild-type animals led to 33 and 42% reduction in 
spontaneous locomotor activity and food intake, respectively, that were not observed in caspase-
1 knockout (KO), IL-1 receptor type 1 (IL-1R1) KO and A2A AR KO mice or in mice 
administered a caspase-1 inhibitor centrally. Finally, adenosine administration increased anxiety-
like behaviors in wild-type mice by 28% in the open field test and by 55% in the elevated zero-
maze. Caspase-1 KO, IL-1R1 KO and A2A AR KO mice were resistant to adenosine-induced 
anxiety-like behaviors. Thus, our results indicate that adenosine can act as an anxiogenic by 
activating caspase-1 and increasing IL-1 in the brain. 
 
 
Introduction 
With a lifetime prevalence of nearly 18% ( Kessler et al., 2005), anxiety disorders 
including generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), panic 
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disorder and post-traumatic stress disorder (PTSD) are among the most common psychiatric 
conditions suffered by Americans and Europeans (Kessler et al., 2005, WHO 2000). In humans, 
the pathogenesis of anxiety is poorly understood but recently new triggers of anxiety have been 
described including oxidative stress (Rammal et al., 2008) and inflammation (Pitsavos et al., 
2006).  
 
Common to these intertwined physiologic processes is the generation of the pleotropic 
cytokine IL-1 (Buttke  & Sandstrom, 1994, Donath et al., 2008). IL-1β is not only a regulator of 
innate immunity, angiogenesis and hematopoiesis but also influences brain-based processes 
including cognition, locomotion, anorexia and anxiety (Johnson et al., 2007, Dantzer et al., 2008, 
Pugh et al., 2001, Me et al., 2003). Canonically, IL-1β exists intracellularly as a pro-form that is 
cleaved to its mature secretable polypeptide by caspase-1 as part of the multiprotein 
inflammasome (Damiano et al., 2004, Bauernfeind et al., 2009). Signals that activate the 
inflammasome are varied but potassium (K+) efflux is a key event that is especially relevant to 
the oligomerization and activation of the NLRP3 inflammasome (Pétrilli et al., 2007). 
 
The amygdala is central to emotive learning (Hamann et al., 1999) and appears critical to 
the aversive state that characterizes anxiety (Davis, 1992). Recently, we demonstrated that the 
purine nucleoside, adenosine, released from cells during oxidative stress activates caspase-1 in 
the amygdala. There are four described ARs that respond to extracellular adenosine (Fredholm et 
al., 2001) with the A2A AR being preferentially expressed in the amygdala when compared to 
the hippocampus (Rosin et al., 1998). As a stimulatory G protein-coupled receptor (GPCR), the 
A2A AR is a well described inducer of K+ efflux. In the brain, A2A AR-dependent K+ efflux has 
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been linked to ATP-sensitive potassium (KATP) channels downstream of protein kinase A (PKA) 
(Kleppisch & Nelson, 1995) as part of a hyperpolarization protection mechanism that guards 
against neuronal excitotoxicity (Popoli et al., 2002). Therefore, this mechanism that helps guard 
against neuronal damage and death may also be an early activator of the neuroimmune system.  
  
In the brain, adenosine is tied to certain behaviorally-related functions including the 
regulation of sleep (Portas et al., 1997), arousal (Lin et al., 1997) and memory (Pereira et al., 
2005). Normally, the cerebral concentration of extracellular adenosine is highest during 
wakefulness (30 nM) than during sleep (24 nM) (Porkka-Heiskanen, 1997, Huston et al., 1996). 
However, in instances of an inflammatory response induced by ischemia, hypoxia and sepsis 
(Martin et al.,  2000, Robertson et al.,  2001, Gorlach, 2005), the extracellular concentration of 
adenosine can easily exceed 50 μM (Hagberg et al., 1987). Therefore, we examined the 
mechanism by which adenosine activates caspase-1 in the brain and if adenosine triggers 
anxiety-like behavior via a mechanism reliant on IL-1.  
 
Methods 
Materials- All reagents and chemicals were purchased from Sigma-Aldrich (St Louis, 
MO) except as noted. All qPCR assays were purchased from Applied Biosystems (Foster City, 
CA). 
 
Animals- Animal use was conducted in accordance with Institutional Animal Care and 
Use Committee approved protocols at the University of Illinois. C57BL/6J (C57 WT) and 
BALB/cJ (BALB/c WT), IL-1R1 knock-out (IL-1R1 KO) on a C57BL/6J background and A2A 
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AR KO mice on a BALB/cJ background were originally purchased from The Jackson Laboratory 
(Bar Harbor, ME). Caspase-1 KO (Casp-1 KO) mice on a C57BL/6J background were kindly 
provided by Dr. Richard Flavell (Yale University School of Medicine, Kuida et al., 1995). Mice 
were group housed (×8 cage) in standard shoebox cages (length 46.9 cm; width 25.4 cm; height 
12.5 cm) and allowed water and food ad libitum. Housing temperature (72 °F) and humidity (45–
55%) were controlled, as was a 12/12 h reversed dark-light cycle (2200–1000 h). Video 
recording of animal behavior was performed under red light using a Sony HDR-XR500V Night 
Shot capable video camera (Tokyo, Japan). Except for locomotor activity which was performed 
as a repeated measure, all treatments at all time points represent separate cohorts of mice. Mice 
were between 8 and 14 weeks of age and the total number of mice utilized was 324. 
 
Perfusions- As we have described (Chiu et al., 2012), mice were euthanized via CO2 
asphyxiation and the left ventricle immediately was pieced with a BD 23 gage 1.25 inch needle 
(Franklin Lakes, NJ) attached to a BD 30 mL syringe. Mice, as indicated, were perfused with 30 
mL of PBS (3 mM KCl, 138 mM NaCl, 8 mM dibasic sodium phosphate, 2 mM monobasic 
potassium phosphate, pH of 7.4) with or without 50 M adenosine, 1 μM 8-(3-
chlorostyryl)caffeine (CSC), 100 nM KT5720 or 200 μM glyburide. For studies in which mice 
were perfused with a high concentration of K+, PBK (130 mM KCl, 3.5 mM NaCl, 1.5 mM 
dibasic sodium phosphate, 2 mM monobasic potassium phosphate, pH of 7.4) was substituted for 
PBS, as indicated. 
 
Caspase-1 activity- As we have described (Chiu et al., 2012), perfused whole brains were 
frozen in liquid nitrogen then freeze fractured in a reaction buffer containing 50 mM NaCl 
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(Fisher Scientific, Fair Lawn, NJ), 10% glycerol, 1 mM DTT, 1 mM EDTA, 1 mM bestatin, 1 
mM pepstatin (EMD4Bioscience, Darmstadt, Germany), 1 mM 4-(2-aminoethyl)benzenesulfonyl 
fluoride hydrochloride and 50 mM HEPES, pH 7.4 (USB Corporation, Cleveland, OH) using a 
Qiagen TissueLyser II (Valencia, CA). Lysates were clarified at 16,000 x g for 15 min at 4º C 
and the supernatant protein concentrations determined using the Bio-Rad DC Protein Assay 
(Hercules, CA) and a BioTek ELx800 Absorbance Microplate Reader (Winooski, VT). 
Supernatant protein concentrations were normalized to 10 mg/ml with reaction buffer. Caspase-1 
activity was determined colorimetrically in the clarified lysates using the caspase-1 substrate Ac-
YVAD-p-nitroaniline (p-NA) (Enzo Life Science, Farmingdale, NY) at a final concentration of 4 
mM. Substrate incubation was at 37º C for the times indicated. Moles of p-NA liberated was 
determined by a standard curve ranging from 0.075 mM to 0.3 mM p-NA (Enzo Life Science, 
Farmingdale, NY). Caspase-1 activity was calculated as (Δ[p-NA]/Δ time)/(total protein). 
Results are expressed as relative change from control. 
 
PKA activity- Perfused whole brains were frozen in liquid nitrogen then freeze fractured 
in reaction buffer containing 50 mM NaF, 50 mM β-glycerolphosphate, 2 mM EDTA, 1 mM 
NaVO4, 5 mM EGTA, 1 mM DTT, 1 mM benzamidine, 10% glycerol, 1:200 Calbiochem 
Protease Inhibitor Cocktail III (Darmstadt, Germany), 1 mM phenylmethysulfonyl fluoride 
(PMSF) and 50 mM HEPES, pH 7.4 using the TissueLyser II. Lysates were clarified and 
supernatant protein concentrations normalized to 10 mg/ml with reaction buffer, as above. PKA 
activity was determined using the Enzo Life Science PKA Kinase Activity Kit. In brief, samples 
were incubated with the kit-provided substrate coated plate for 90 min and phosphorylated 
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tetramethylbenzidine measured spectrophotometrically at 450 nm. Results are expressed as 
relative change from control.  
 
cAMP concentration- Perfused whole brains were frozen in liquid nitrogen then freeze 
fractured in reaction buffer containing 138 mM NaCl, 8 mM Na2HPO4, 2 mM KH2PO4, 3 mM 
KCl, 50 mM NaF, 50 mM β-glycerolphosphate, 2 mM EDTA, 1 mM NaVO4, 5 mM EGTA, 1 
mM benzamindine, 10% glycerol, 1:200 Calbiochem Protease Inhibitor Cocktail III, 1 mM 
PMSF, 500 µM 3-isobutyl-1-methylxanthine, 100 µM RO201724 and 50 mM HEPES, pH 7.4 
using the TissueLyser II. Lysates were clarified and supernatant protein concentrations 
normalized to 10 mg/ml with reaction buffer, as above. cAMP concentration was determined 
using the Promega cAMP-Glo Assay (Madison, WI). In brief, samples were incubated for 30 
min and the methyl ester luciferin/luciferase reaction quantified using a Fuji LAS-4000 Imaging 
System (Tokyo, Japan).   
 
IL-1 concentration- As above, perfused whole brains and livers were frozen in liquid 
nitrogen then freeze fractured in a homogenization buffer containing 50 mM NaCl, 10% 
glycerol, 1:200 Calbiochem Protease Inhibitor Cocktail III and 50 mM HEPES, pH 7.4 using the 
TissueLyser II. Lysates were clarified and supernatant protein concentrations measured as above. 
IL-1β was measured in 50 L of lysate using the Bio-Rad Bio-Plex Promouse Cytokine Group I 
Cytokine Assay on a Luminex 100 System (Austin, TX) by methods similar to those we have 
described (Chiu et al., 2012). Results are expressed as (pg IL-1β)/(μg total protein).  
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Quantitative PCR (qPCR)- As we have described (Chiu et al., 2012, York et al., 2012), 
RNA was isolated from perfused whole brains. RNA was reverse transcribed using the Applied 
Biosystems High-Capacity cDNA Reverse Transcription Kit (PN 4368813). The Applied 
Biosystems TaqMan Gene Expression primers used were: A2A AR (Mm00802075_m1), IL-1α 
(Mm99999060_m1), IL-1β (Mm99999061_mH), IL-1 receptor type 1 (IL-1R1) 
(Mm01226959_m1), IL-1 receptor type 2 (IL-1R2) (Mm00439622_m1), IL-1 receptor 
antagonist (Il-1RA) (Mm01337566_m1) and caspase-1 (Mm00438023_m1). qPCR was 
performed on a Applied Biosystems 7900 HT Fast Real-Time PCR System using Applied 
Biosystems TaqMan Universal PCR Master Mix. To compare gene expression, a parallel 
amplification of endogenous RPS3 (Mm00656272_m1) was performed. Reactions with no 
reverse transcription and no template were included as negative controls. Relative quantitative 
evaluation of target gene to RPS3 was performed by comparing ΔCts, where Ct is the threshold 
concentration. 
 
Serum adenosine - 500 μL of blood was mixed 1:2 with 138 mM NaCl, 8 mM Na2HPO4, 
2 mM KH2PO4, 3 mM KCl, 5.9 mM NaHCO3, 5.6 mM dextrose, 2.15 mM CaCl2, 1% DMSO, 
and 120 μM dipyridamole. Samples were centrifuged at 3650 x g for 10 min at 4⁰C and proteins 
precipitated by addition of 2% v/v of 70% (12N) perchloric acid with re-centrifuged at 3650 x g 
for 10 min at 4⁰C. Adenosine was determined on a 5500 QTRAP LC/MS/MS (AB Sciex, Foster 
City, CA) with a 1200 series HPLC (Agilent Technologies, Santa Clara, CA). LC separation was 
performed on a Phenomenex Kinetex 2.6 u PFP column (4.6 x 100mm) (Torrence, CA). Mobile 
phase A was 0.1% formic acid in water. Mobile phase B was 0.1% formic acid in acetontrile. 
Flow rate was 0.3 mL/min and the linear gradient was: 0-1 min, 100% A; 5 min, 90% A; 10 min, 
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80% A; 12-18 min, 0% A; and 18.5-25 min, 100% A with an auto-sampler temperature of 5ºC. 
The injection volume was 5 µL. Mass spectra were acquired with positive electrospray ionization 
with an ion spray voltage of 5500 V at a source temperature of 450 ºC. The curtain gas, ion 
source gas 1 and ion source gas 2 were 35, 50, and 65, respectively. Multiple reaction monitoring 
was used to quantify adenosine m/z 268.1 --> m/z 136.1, inosine m/z 269.1 --> m/z 137.1 and 
internal standard caffeine m/z 195.1 --> m/z 138.1. 
 
Injectables- Adenosine (Akorn, Lake Forest, IL) in PBS was administered IP at a dose of 
2 mg/kg/mouse. Ac-YVAD-CMK (Bachem, Torrance, CA) was administered ICV, as we have 
described (Johnson et al., 2007, Chiu et al., 2012), at a dose of 50 ng/uL/mouse, 30 min prior to 
IP adenosine injection.   
 
ICV cannulation- As we have described (Johnson et al., 2007, Chiu et al., 2012), mice 
were anesthetized with an IP injection of sodium ketamine hydrochloride/xylazine hydrochloride 
solution delivering 80 mg/kg ketamine and 12 mg/kg xylazine. Animals were placed in a David 
Kopf Instruments stereotaxic instrument (Tujunga, CA), Plastics One mouse-specific brain 
infusion cannulas (Roanoke, VA) were placed 0.6 mm posterior, 1.5 mm lateral to the bregma 
and to extend 2.5 mm ventral from the surface of the skull. Cannulas were fixed to the skull with 
Plastics One cyanoacrylate gel adhesive and protected by a Plastics One guard. Mice were 
allowed 7 days to recover prior to treatment. 
 
Locomotion- Spontaneous locomotor activity was measured by continuous videography 
followed by analysis with automated video tracking software (Noldus Information Technology 
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EthoVision XT 7, Leesburg, VA), as we have described (York et al., 2013). Immediately after 
treatment, mice were video recorded in their home cage for 60 min. Distance moved was binned 
into consecutive 15 min intervals. Results are presented as percent control.  
 
Food intake- Immediately after adenosine injection, mice were allowed ad libitum access 
to food in a 6 cm diameter × 1.5 cm glass bowl for 60 min. As we have described (York et al., 
2012), food consumption was calculated as the difference in weight of food before and after. 
Results are presented as percent control.  
 
Open field test- Open field testing was performed as we have described (York et al., 
2012). In brief, mice were placed in a novel open field arena (66 cm length x 45.7 cm width x 
22.9 cm height) 30 min after adenosine injection. Lighting was positioned to create a 9 cm 
shadow from each side wall. Mice were video recorded for 5 min. Total distance traveled, time 
spent in the non-shadowed and shadowed areas of the arena were determined using Noldus 
Information Technology EthoVision XT 7. Percent of time (sec) in the non-shadowed area 
(center) was calculated by dividing time spent in the center by total time (300 sec) in the arena. 
Results are presented as percent control.  
 
Elevated zero-maze- Elevated zero-maze testing was performed as we have described 
(31). In brief, 30 min after adenosine injection mice were placed in a circular elevated zero-maze 
(22.5 cm in diameter, track width of 2.75 cm, elevated 33 cm above the floor). The maze was 
divided into two open quadrants and two enclosed quadrants. Mice were video recorded for 5 
min. Total distance traveled, time spent in the open and closed arms of the maze were 
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determined using Noldus Information Technology EthoVision XT 7. Percent of time (sec) in the 
open area was calculated by dividing time spent in the center by total time (300 sec) in the arena. 
Results are presented as percent control.  
 
Statistics- All data are presented as mean ± SEM. Data was analyzed using Sigma Plot 
11.2 (Systat Software, Chicago, IL). To test for statistical differences, a one-way or two-way 
ANOVA was with repeated measurements where needed. Tukey’s test was used for post-hoc 
pair-wise multiple comparison procedures. Where indicated, raw data was transformed to attain 
equal variance. Statistical analysis included testing for time x treatment interactions when 
needed. Statistical significance was denoted at p < 0.05. 
 
Results 
Inhibition of potassium efflux prevents adenosine-dependent activation of caspase-1 in 
the brain- Fig.3.1A demonstrates that activation of caspase-1 by adenosine is prevented when 
adenosine is co-perfused with 130 mM K+ (PBK) when compared to 3 mM K+ (PBS). Main 
effect of interaction, p < 0.001 (PBK vs. adenosine + PBK, 1.07 ± 0.10 vs. 0.93 ± 0.09, p = 
0.563: PBS vs. adenosine + PBS, 1.00 ± 0.06 vs. 2.29 ± 0.32, p < 0.001: PBS vs. PBK, 1.00 ± 
0.06 vs. 1.07 ± 0.10, p = 0.776: adenosine +PBS vs. adenosine + PBK, 2.29 ± 0.32 vs. 0.93 ± 
0.09, p < 0.001). Fig.3. 1B shows that activation of caspase-1 by adenosine is blocked when 
adenosine is co-perfused with the KATP channel blocker, glyburide. Main effect of adenosine, p = 
0.008 (glyburide vs. adenosine + glyburide, 1.06 ± 0.26 vs. 1.29 ± 0.16, p = 0.427: PBS vs. 
adenosine + PBS, 1.00 ± 0.14 vs. 1.88 ± 0.18, p = 0.003: PBS vs. glyburide (1.00 ± 0.14 vs. 1.06 
± 0.26, p = 0.806: adenosine vs. adenosine + glyburide, 1.88 ± 0.18 vs. 1.29 ± 0.16, p = 0.036). 
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The PKA inhibitor KT5720 blocks activation of caspase-1 by adenosine- Fig.3.2A shows 
that activation of caspase-1 by adenosine is blocked when adenosine is co-perfused with 
KT5720. Main effect of interaction, p = 0.004 (KT5720 vs. adenosine + KT5720, 1.07 ± 0.20 vs. 
1.15 ± 0.13, p = 0.701: PBS vs. adenosine, 1.00 ± 0.07 vs. 2.13 ± 0.17, p < 0.001: PBS vs. 
KT5720, 1.00 ± 0.07 vs. 1.07 ± 0.20, p = 0.755: adenosine vs. adenosine + KT5720, 2.13 ± 0.17 
vs. 1.15 ± 0.13, p < 0.001). Fig.3.2B&C demonstrate that PKA activity and the concentration of 
cAMP are increased in the brain after adenosine perfusion, respectively (saline vs. adenosine, 
1.00 ± 0.06 vs. 1.52 ± 0.16, p = 0.009: saline vs. adenosine, 1.00 ± 0.02 vs. 1.64 ± 0.19, p = 
0.015). 
 
Activation of caspase-1 by adenosine is blocked by selective A2A AR antagonism and in 
A2A AR KO mice- Fig.3.3A shows that activation of caspase-1 by adenosine is prevented when 
adenosine is co-perfused with the selective A2A AR antagonist CSC. Main effect of interaction, 
p < 0.001 (CSC vs. adenosine +CSC, 1.23 ± 0.15 vs. 1.08 ± 0.06, p = 0.196: PBS vs. adenosine, 
1.00 ± 0.05 vs. 1.77 ± 0.05, p < 0.001: PBS vs. CSC, 1.00 ± 0.05 vs. 1.23 ± 0.15, p = 0.053: 
Adenosine vs. adenosine + CSC, 1.77 ± 0.05 vs. 1.08 ± 0.06, p < 0.001). Fig.3.3B demonstrates 
that A2A AR KO mice are protected from adenosine-dependent activation of caspase-1. Main 
effect of interaction, p = 0.015 (A2A AR KO vs. adenosine in A2A AR KO, 0.90 ± 0.21 vs. 1.01 
± 0.19, p = 0.610: WT vs. adenosine in WT, 1.00 ± 0.08 vs. 1.83 ± 0.29, p < 0.001: WT vs. A2A 
AR KO, 1.00 ± 0.084 vs. 0.90 ± 0.21, p = 0.553: adenosine in WT vs. adenosine in A2A AR KO, 
1.83 ± 0.29 vs. 1.01 ± 0.19, p = 0.001) 
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Adenosine increases IL-1β protein in the brain but not the liver- Table 1 demonstrates 
that IL-1β protein in the brain, but not the liver, is increased after adenosine perfusion. 
Adenosine did not induce gene transcripts for IL-1β, IL-1α, IL-1R1, IL-1R2, IL-1RA or caspase-
1 (data not shown). Table 2 shows that relative gene expression of A2A ARs is greater in the 
amygdala than hippocampus. 
 
Adenosine activates caspase-1 in the brain while reducing locomotor activity and food 
intake. Fig.3.4A demonstrates that brain caspase-1 activity is increased by 33% 15 min after IP 
injection of adenosine (saline vs. adenosine, 1.00 ± 0.07 vs. 1.33 ± 0.02, p < 0.001). 
Concordantly, the serum adenosine concentration was increased by two-fold 15 min after IP 
injection of adenosine (saline vs. adenosine, 0.399 ± 0.091 μM vs. 0.829 ± 0.051 μM, p = 0.007). 
Fig.3.4B shows that in C57 WT mice adenosine decreases locomotor activity by 30% 30 through 
75 min after injection (saline vs. adenosine: 0-15 min, 100.00 ± 6.24 vs. 98.32 ± 4.33, p = 0.823; 
15-30 min, 100.00 ± 9.05 vs. 94.78 ± 8.05, p = 0.669; 30-45 min, 100.00 ± 15.94 vs. 67.48 ± 
5.57, p = 0.05; 45-60 min, 100.00 ± 12.00 vs. 69.49 ± 6.97, p = 0.05, 60-75 min, 100.00 ± 8.96 
vs. 64.93 ± 5.16, p = 0.006; 75-90 min, 100.00 ± 11.30 vs. 72.75 ± 8.32, p = 0.079; 90-105 min, 
100.00 ± 11.76 vs. 112.01 ± 16.92, p = 0.590).Figs. 4C & D show that Casp-1 KO and IL-1R1 
KO mice are resistant to adenosine-dependent reductions in locomotor activity (Casp-1 KO) 
saline vs. adenosine: 0-15 min, 100.00 ± 4.83 vs. 92.98 ± 4.56, p = 0.312; 15-30 min, 100.00 ± 
9.00 vs. 109.76 ± 8.78, p = 0.454; 30-45 min, 100.00 ± 8.06 vs. 94.49 ± 13.48, p = 0.719; 45-60 
min, 100.00 ± 11.41 vs. 89.95 ± 7.14, p = 0.596; (IL-1R1 KO) saline vs. adenosine: 0-15 min, 
100.00 ± 8.64 vs. 113.26 ± 9.22, p = 0.319; 15-30 min, 100.00 ± 17.34 vs. 149.49 ± 21.96, p = 
0.108; 30-45 min, 100.00 ± 22.57 vs. 149.48 ± 33.27, p = 0.298; 45-60 min, 100.00 ± 22.64 vs. 
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114.82 ± 22.20, p = 0.650. Figs.4E & F show, respectively, that in BALB/c WT mice adenosine 
decreases locomotor activity by 50% 45 min after injection and that A2A AR KO mice are 
resistant to adenosine-dependent reductions in locomotor activity (BALB/c WT) saline vs. 
adenosine: 0-15 min, 100.00 ± 20.94 vs. 83.31 ± 13.51, p = 0.455; 15-30 min, 100.00 ± 23.04 vs. 
97.53 ± 13.09, p = 0.914; 30-45 min, 100.00 ± 17.70 vs. 105.83 ± 19.92, p = 0.803; 45-60 min, 
100.00 ± 13.34 vs. 50.25 ± 18.87, p = 0.015; (A2A AR KO) saline vs. adenosine: 0-15 min, 
100.00 ± 14.45 vs. 81.96 ± 10.97, p = 0.420; 15-30 min, 100.00 ± 11.45 vs. 102.00 ± 13.62, p = 
0.931; 30-45 min, 100.00 ± 10.77 vs. 92.27 ± 15.19, p = 0.741; 45-60 min, 100.00 ± 4.41 vs. 
95.48 ± 10.79, p = 0.808. Figs.4G & H demonstrate that Casp-1 KO mice, IL-1R1 KO mice and 
A2A AR KO mice are resistant to adenosine-dependent reductions in food intake (C57 WT) 
saline vs. adenosine, 100.00 ± 10.91 vs. 58.33 ± 10.11, p = 0.006; (Casp-1 KO) saline vs. 
adenosine, 100.00 ± 9.45 vs. 150.00 ± 18.26, p = 0.029; (IL-1R1 KO) saline vs. adenosine, 
100.00 ± 12.60 vs. 86.67 ± 15.07, p = 0.499; (BALB/c WT) saline vs. adenosine, 100.00 ± 12.48 
vs. 61.14 ± 7.87, p = 0.006; (A2A AR KO) saline vs. adenosine, 100.00 ± 6.79 vs. 102.08 ± 9.13, 
p = 0.875. 
 
Central administration of the caspase-1 inhibitor Ac-YVAD-CMK blocks adenosine-
induced reductions in locomotor activity and food intake - Figs.5A & B show that C57 WT 
administered Ac-YVAD-CMK ICV are protected from adenosine-induced decrease in locomotor 
activity and food intake, respectively (locomotion) saline vs. adenosine: 0-15 min, 100.00 ± 
10.92 vs. 61.14 ± 2.61, p = 0.013; 15-30 min, 100.00 ± 45.41 vs. 73.64 ± 5.48, p = 0.468; 30-45 
min, 100.00 ± 31.94 vs. 36.08 ± 7.75, p = 0.009; 45-60 min, 100.00 ± 21.41 vs. 40.32 ± 5.42, p = 
0.018; Ac-YVAD-CMK vs. adenosine: 0-15 min, 100.00 ± 13.50 vs. 74.39 ± 6.53, p = 0.080; 15-
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30 min, 100.00 ± 24.51 vs. 69.02 ± 10.93, p = 0.395; 30-45 min, 100.00 ± 12.09 vs. 93.17 ± 
7.40, p = 0.868; 45-60 min, 100.00 ± 18.50 vs. 137.96 ± 14.10, p = 0.109; (food intake) saline vs. 
adenosine, 100.00 ± 9.62 vs. 53.33 ± 9.72, p = 0.012; Ac-YVAD-CMK vs. adenosine, 100.00 ± 
21.25 vs. 104.17 ± 26.90, p = 0.905. 
 
Adenosine causes anxiety-like behavior - Fig.3.6A shows that mice administered 
adenosine 30 min prior to open field testing exhibited a 28% decrease in percentage of time spent 
in the center area while Casp-1 KO, IL-1R1 KO and A2A AR KO mice were resistant (C57 WT) 
saline vs. adenosine: 100.00 ± 7.46% vs. 72.45 ± 6.86%, p = 0.02; (Casp-1 KO) 100.00 ± 
27.61% vs. 88.75 ± 14.63%, p = 0.714; (IL-1R1 KO) saline vs. adenosine: 100.00 ± 18.56% vs. 
88.24 ± 11.91%, p = 0.646; (BALB/c WT) saline vs. adenosine: 100.00 ± 3.81% vs. 66.75 ± 
7.47%, p = 0.007; (A2A AR KO) saline vs. adenosine: 100.00 ± 14.36% vs. 108.82 ± 10.43%, p 
= 0.630. Fig.3.6B demonstrates that adenosine did not curtail mouse locomotion within the open 
field testing arena (C57 WT) saline vs. adenosine: 100.00 ± 6.12% vs. 115.58 ± 10.05%, p = 
0.231; (Casp-1 KO) saline vs. adenosine: 100.00 ± 9.60% vs. 115.02 ± 6.33%, p = 0.210; (IL-
1R1 KO) saline vs. adenosine: 100.00 ± 12.91% vs. 108.02 ± 4.40%, p = 0.632; (BALB/c WT) 
saline vs. adenosine: 100.00 ± 12.43% vs. 107.98 ± 12.84%, p = 0.671; (A2A AR KO) saline vs. 
adenosine: 100.00 ± 9.26% vs. 97.20 ± 7.43%, p = 0.821. Fig.3.6C shows that mice administered 
adenosine 30 min prior to open field testing exhibited a 55% decrease in percentage of time spent 
in the open arms of the elevated zero-maze while Casp-1 KO, IL-1R1 KO and A2A AR KO mice 
were resistant (C57 WT) saline vs. adenosine: 100.00 ± 21.23% vs. 45.25 ± 13.74%, p = 0.05; 
(Casp-1 KO) 100.00 ± 15.30% vs. 101.47 ± 15.05%, p = 0.947; (IL-1R1 KO) saline vs. 
adenosine: 100.00 ± 22.91% vs. 139.16 ± 27.19%, p = 0.296; (BALB/c WT) saline vs. 
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adenosine: 100.00 ± 18.5% vs. 41.69 ± 7.82%, p = 0.027; (A2A AR KO) saline vs. adenosine: 
100.00 ± 45.18% vs. 92.99 ± 14.44%, p = 0.887. Fig.3.6D demonstrates that adenosine did not 
curtail mouse locomotion within the elevated zero-maze (C57 WT) saline vs. adenosine: 100.00 
± 4.45% vs. 106.65 ± 5.52%, p = 0.371; (Casp-1 KO) saline vs. adenosine: 100.00 ± 2.89% vs. 
119.70 ± 10.68%, p = 0.222; (IL-1R1 KO) saline vs. adenosine: 100.00 ± 3.08% vs. 103.72 ± 
4.76%, p = 0.818; (BALB/c WT) saline vs. adenosine: 100.00 ± 17.37% vs. 108.53 ± 8.45%, p = 
0.674; (A2A AR KO) saline vs. adenosine: 100.00 ± 5.18% vs. 113.77 ± 11.38%, p = 0.313.  
 
Discussion 
The novel data that we present show for the first time that the increase in anxiety 
(thigmotaxis), decrease in food intake and decrease in locomotor activity caused by adenosine 
are absent in mice with defects in the A2A AR, caspase-1, IL-1ß to IL-1R1 pathway. These data 
strongly implicate the induction of IL-1ß protein maturation as a causal mechanism for 
adenosine-linked behaviors. Our ex vivo data indicate that adenosine initiates the behavioral 
cascade by engaging the A2A AR, increasing intracellular cAMP, activating PKA and triggering 
K+ efflux. This signaling pathway is the initiating event for caspase-1 activation, IL-1ß protein 
elevation and subsequent behavioral changes, including anxiety.  
 
Anxiety disorders and pro-inflammatory Th1-like responses have long been linked (Maes 
et al., 1998), but the pathways involved have remained elusive. Recently, adenosine receptors 
have been postulated to have a role in anxiety due to a variety of anecdotal accounts tying 
consumption of caffeinated drinks to self-perceived anxious/jittery behaviors (Braun et al., 2011, 
Lara et al., 2010, Maximino et al., 2011, Lee et al., 1985). However, as a competitive pan-AR 
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blocker, caffeine appears to afford protection against some 
neuroinflammatory/neurodegenerative diseases like Alzheimer’s disease (AD) (Arendash et al., 
2006, Arendash & Cao, 2010, Eskelinen & Kivipelto, 2010) indicating that adenosine in the 
brain can act as a proinflammatory agent (Chiu et al., 2012, Yu et al., 2004). Since IL-1 is a well 
described anxiogenic (Connor et al., 1998, Koo & Duman, 2009), the proinflammatory actions of 
adenosine might, in fact, promote an anxious phenotype. Support for this contention is seen in 
Fig.3.1 where we show that perfused adenosine doubles brain caspase-1 activity confirming our 
recent finding that adenosine is an activator of caspase-1 in the brain (Chiu et al., 2012).  
 
As part of the multiprotein inflammasomes, caspase-1 is a critical generator of mature IL-
1 (Bauernfeind et al., 2009). How danger signals are recognized by the inflammasome is not 
entirely known but K+ efflux is an important trigger in caspase-1 activation (Gross et al., 2011). 
Fig.3.1 demonstrates that an excess of extracellular potassium prevents adenosine-dependent 
activation of caspase-1 as does the use of the KATP channel blocker glyburide (Lamkanfi et al., 
2009). Thus, adenosine-dependent activation of caspase-1 appears dependent on KATP channel 
mediated potassium efflux in a manner similar to lipopolysaccharide (LPS)-treated macrophages 
where NLRP3 inflammasome-dependent activation of caspase-1 can be prevented by raising the 
extracellular K+ concentration above 70 mM (Pétrilli et al., 2007, Fernandes-Alnemri et al., 
2007) or by antagonizing KATP channels with sulfonylureas (Lamkanfi et al., 2009, Lamkanfi & 
Dixit, 2009).   
 
How LPS, which interacts with Toll-like receptor 4 (TLR4), causes K+ efflux is still 
unclear (Scheel et al., 2006, Jo et al., 2011), but for GPCRs, like the ARs, the mechanisms by 
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which K+ efflux is triggered is much better defined (Kleppisch & Nelson, 1995, Mathie, 2007). 
Importantly, the A2A AR is a well described inducer of K+ efflux through a pathway reliant on 
increased intracellular cAMP, activation of PKA and opening of KATP channels (Kleppisch & 
Nelson, 1995). Fig.3.1&2 show that the competitive PKA inhibitor KT5720 prevented 
adenosine-dependent-activation of caspase 1 and that caspase-1 activation was reliant on the 
A2A AR. These findings were not unexpected in light of our previous work showing that that an 
A1/A2A AR inhibitor cocktail blocked adenosine-dependent activation of caspase-1 (Chiu et al., 
2012). Since the A1 AR is a Gi-linked GPCR that inhibits intracellular cAMP production (Stiles, 
1986), it was unlikely that the A1 AR was the upstream receptor responsible for adenosine-
dependent caspase-1 activation in the brain. In general, ligand bound A2A ARs increase 
intracellular cAMP concentration (Wu et al., 2013). Therefore, adenosine-dependent activation 
of caspase-1 in the brain leading to increased brain IL-1 (Table 1) appears reliant on A2A ARs, 
PKA and KATP channel mediated K
+ flux. 
  
Central IL-1, especially in rodents, promotes anxiety-like behavior as first demonstrated 
in rats administered ICV IL-1β (Connor et al., 1998). Most studies examining the behavioral 
effects of IL-1 have been developed from the sickness behavior paradigm in which peripheral 
infection, often modelled by IP LPS administration, triggers brain-based production of IL-1. 
Fig.3.4 shows that IP administration of adenosine increases brain caspase-1 activity which was 
coupled to a 2-fold increase in serum adenosine. Importantly, these increases in adenosine and 
caspase-1 were linked to the classic IL-1-associated sickness symptoms of a transient decrease in 
locomotion and food intake that resolved by 75 mins post injection. Evidence that caspase-1 and 
IL-1 were responsible for these adenosine-dependent behaviors was gleaned from caspase-1 KO 
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and IL-1R1 KO mice which demonstrated a resistance to these adenosine-induced behaviors 
(Fig.3.4). Interestingly, caspase-1 KO mice appeared to have an inverse phenotype because food 
intake increased in response to adenosine. Since IL-1R1 KO mice did not show this same 
behavior, it is likely that another caspase-1-activated bioactive is involved. A probable candidate 
is IL-18 since pro-IL-18 is matured by caspase-1 (Sansonetti et al., 2000) and IL-18 KO mice 
have an obese phenotype (Netea et al., 2006). As was anticipated, A2A AR KO mice were 
resistant to adenosine-induced reductions in locomotion and food intake supporting our 
contention that adenosine through A2A AR activates caspase-1 leading to IL-1-dependent 
biobehaviors.   
 
Fig.3.5 shows that central administration of the caspase-1 inhibitor Ac-YVAD-CMK 
prevented adenosine-induced loss of locomotion and food intake. These findings support the role 
of brain-based caspase-1 and by extension IL-1 as the drivers of biobehaviors triggered by 
peripheral elevations in extracellular adenosine. Additional support for the above is derived from 
our previous work in which hypoxia/reoxygenation-induced extracellular adenosine caused 
adenosine-dependent activation of caspase-1 in the brain but not in the liver (Chiu et al., 2012). 
Since oxidative stress and other metabolic-related dysfunctions are the most common 
precipitates of elevated serum adenosine (Rego et al.,  2000, Lavie, 2003, Barsotti & Ipata, 
2004), our finding indicate that conditions unrelated to microbial driven inflammation can 
activate caspase-1 in the brain and trigger IL-1 associated adverse biobehaviors. Furthermore, 
while certain psychiatric conditions appear to emerge in association with proinflammatory 
conditions like obesity and type 2 diabetes (Anderson et al.,  2001, Simon et al., 2006, Das-
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Munshi et al., 2007, Petry et al.,  2008), causation related to TLRs has not been clearly 
demonstrated suggesting that danger signals recognized by non-TLRs are important.  
 
 While induced reductions in spontaneous locomotion and ad libitum food intake are often 
associated with sickness symptoms (Dantzer et al., 2008), these relatively non-specific behaviors 
are seen in a variety of conditions unrelated to sickness including anxious-like states (Schneider 
et al., 2012). As Fig.3.6 demonstrates, adenosine decreased the time spend in the center area of 
the open field test but given the novel/stressful open field environment mouse locomotion in this 
test was not reduced. Similarly, adenosine-induced a decrease the time spent in the open arms of 
the elevated zero-maze with no effects on overall motor activity in the novel arena. These 
findings underscore the difference between adenosine-induced biobehaviors and those seen in 
classic TLR-mediated sickness symptoms or sickness behaviors secondary to IP IL-1 
administration. Classic sickness usually does not manifest until 2 hrs post LPS or IL-1 
administration and loss of function such as reduced locomotion cannot be normalized by 
changing the environment or provocation with a noxious stimulus (Dantzer et al., 2008). The 
cause for this response delay is that LPS and IL-1 do not cross the blood brain barrier 
efficiently and/or act peripherally to stimulate central IL-1 transcription prior to inflammasome 
activation (Layé et al., 1995). In contrast, peripheral adenosine can easily and rapidly access the 
CNS (Li et al., 2001) where without increasing IL-1 transcription (data not shown) it can, within 
30 min, trigger anxiety like behavior in an A2A AR-, caspase-1- and IL-1R1-dependent fashion 
(Fig.3.6).  
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 Although a direct role for adenosine in anxiety has not been previously demonstrated, 
such an action is suggested. In animal models, caffeine at a moderate dose (30 mg/kg) increases 
the time rats spend in the open arms of an elevated plus maze (Garcia et al., 2011) indicating that 
a blockade of adenosine signaling might be anxiolytic. Furthermore, zebra fish with early life 
anxiety-like behavior can be made less anxious with caffeine (Khor et al., 2013). However, why 
caffeine is controversial in the context of human anxiety may be due to the dose of caffeine and 
the natural distribution of adenosine receptors. For instance, zebra fish develop anxiety-like 
behaviors at a high dose of caffeine (100 mg/kg) but not at a low dose (10 mg/kg) (Maximino et 
al., 2011). Interestingly, administration of an A1 AR but not A2A AR antagonist increases 
anxiety-like behavior (Maximino et al., 2011), suggesting that unopposed activation of PKA is 
anxiogenic (Keil et al., 2012). Therefore, the anxiogenic effects of high-dose caffeine may be 
mediated via A1 inhibition which likely bypasses caffeine-mediated blockade of A2A AR 
signaling. In addition, as we show in Table 2 and others have demonstrated (Rosin et al., 1998), 
the location of A2A ARs in the brain is primarily in the amygdala and striatum and manipulation 
of amygdala-based neuronal activity can cause anxiety like behavior in mice (Tye et al., 2011). 
Finally, human anxiety has a link to adenosine. Coincident with elevated plasma adenosine is a 
higher prevalence of psychiatric mood disorders especially anxiety (Henningsen et al.,  2003, 
Cella et al.,  2011, Duley et al.,  2000). In sum, physiological levels of extracellular adenosine 
are important to selectively inhibiting neurotransmission via hyperpolarization of excitatory 
synapses (Lambert & Teyler, 1991, Prince & Stevens, 1992). However, in deleterious conditions 
where excessive adenosine is present such as undue alcohol ingestion, sterile inflammation, 
tissue injury and hypoxia/ischemia (Winn et al., 1981, Karmouty-Quintana et al., 2013, Spinetta 
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et al., 2008) this same mechanism of hyperpolarization appears to trigger casapse-1 activation 
and generation of IL-1 that causes adverse biobehaviors that include anxiety. 
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CHAPTER 4: HYPOXIA/REOXYGENATION INCREASE CASPASE-1 ACTIVITY IN 
NEURONS THROUGH THE A2A ADENOSINE RECEPTOR CONTRIBUTING TO 
ANXIETY 
 
Abstract 
 Anxiety is one of the most prevalent comorbidity associated with acute lung injury (ALI) 
and acute respiratory distress syndrome (ARDS). Activation of the innate immune system is a 
known inducer of anxiety-like behaviors. In adult male mice, we found that hypoxia increased 
circulating adenosine concentration by more than 2.5-fold. Moreover, we see that hypoxic mice 
displayed four times greater staining for caspase-1 activity in the amygdala when compared to 
normoxic controls. Finally, hypoxia increased anxiety-like behaviors in wild-type mice by 45 
and 86% as measured in the open field test and elevated zero-maze, respectively, while A2A AR 
KO mice were resistant to hypoxia-induced anxiety-like behaviors.  Our results indicate that 
hypoxia induces anxiety-like behaviors by increasing adenosine signaling via A2A AR to 
increase caspase-1 activity. 
 
Introduction 
 At a rate of 20 - 40%, anxiety disorders are more prevalent in patients of acute lung 
injury (ALI) or acute respiratory distress syndrome (ARDS) than the general public (Hough & 
Herridge, 2012; Kessler et al., 2005) where psychiatric symptoms are seen even 2 years after 
ARDS (Hopkins et al., 2010). Common in ARDS patients is the progression of inflammation as 
well as elevation in extracellular adenosine (Hart et al., 2008).  Recently, we demonstrated that 
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increases in extracellular adenosine can trigger anxiety-like behaviors via caspase-1 activation 
and subsequent IL-1β release. 
  
 The loss of oxygen to the brain can activate the interleukin (IL)-1 arm of the 
neuroimmune system where psychological dysfunction such as amnesia and social withdrawal 
can occur (Johnson et al., 2007; Chiu et al., 2012). A common process involved in neuroimmune 
activation is the generation of the proinflammatory cytokine, IL-1β (Buttke  & Sandstrom, 1994; 
Donath et al., 2008). Basal levels of brain-based IL-1 is required for cognitive function (Dantzer 
et al., 2008), while excessive concentration can be indicative of brain injury (Ma et al., 2003). 
IL-1 is involved in hypoxia and ischemia (Touzani et al., 1999), however, the mechanism 
involved in IL-1 release remains unclear. Previously, we have demonstrated that hypoxia and 
reoxygenation can lead to an increase in caspase-1 activity while this increase is dependent on 
activation of the adenosine receptors (Chiu et al., 2012). Caspase-1 exists as a proenzyme 
(Damiano et al, 2004) and requires proteolytical cleavage by the Nod-like receptor 
inflammasome (Miao et al, 2011). Once activated, active caspase-1 can produce the secretable 
form of IL-1β from pro-IL-1β (Bauernfeind et al, 2009).  
 
 Reoxygenation after hypoxia is can bolster recovery as well as inflict damage (González-
Correa et al., 2007), cell death (Saikumar et al., 1998) and inflammation (Johnson et al., 2007, 
Chiu et al., 2012). Importantly, hypoxia/reoxygenation can increase extracellular adenosine from 
30-300 nM to 10-50 μM concentration (Rudolphi et al., 1997; Hagberg et al., 1987; Guinzberg et 
al., 2006). Similarly, inflammation due to septic shock can also increase extracellular adenosine 
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as well as IL-1 (Martin et al., 2000; Cannon et al., 1990). Importantly, we previously showed that 
adenosine administration can elicit an increase in caspase-1 activity via A2A AR. Therefore, we 
examined the mechanism by which hypoxia/reoxygenation-induced anxiety-like behavior is 
reliant on AR and caspase-1.   
 
Methods 
 Materials- All reagents and chemicals were purchased from Sigma-Aldrich (St Louis, 
MO) except as noted.  
 
Animals- Animal use was conducted in accordance with Institutional Animal Care and 
Use Committee approved protocols at the University of Illinois. C57BL/6J (C57 WT) and 
BALB/cJ (BALB/c WT), A2A AR KO mice on a BALB/cJ background were originally 
purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were group housed (×8 cage) 
in standard shoebox cages (length 46.9 cm; width 25.4 cm; height 12.5 cm) and allowed water 
and food ad libitum. Housing temperature (72 °F) and humidity (45–55%) were controlled, as 
was a 12/12 h reversed dark-light cycle (2200–1000 h). Video recording of animal behavior was 
performed under red light using a Sony HDR-XR500V Night Shot capable video camera (Tokyo, 
Japan). All treatments at all time points represent separate cohorts of mice. Mice were between 8 
and 14 weeks of age and the total number of mice utilized was 125. 
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 Hypoxia/Reoxygenation- As we have previously described (Sherry et al., 2009a; Sherry et 
al., 2009b; Chiu et al., 2012), mice (n = 16/episode) were transferred from their home cages to a 
BioSperix ProOx/A-Chamber Biological Atmosphere System (Biospherix, Lacona NY) and 
subjected to either a 6% oxygen + 94% nitrogen environment (hypoxia) or an atmospheric air 
environment (normoxia) for 2 h. After exposure mice were returned to their home cages.  
 
Injectables- Biotin-YVAD-CMK (AnaSpec, CA) was administered ICV, as we have 
described (Johnson et al., 2007; Chiu et al., 2012), at a dose of 50 ng/uL/mouse, 30 min prior to 
hypoxia 
 
ICV cannulation- As we have described (Johnson et al., 2007; Chiu et al., 2012), mice 
were anesthetized with an IP injection of sodium ketamine hydrochloride/xylazine hydrochloride 
solution delivering 80 mg/kg ketamine and 12 mg/kg xylazine. Animals were placed in a David 
Kopf Instruments stereotaxic instrument (Tujunga, CA), Plastics One mouse-specific brain 
infusion cannulas (Roanoke, VA) were placed 0.6 mm posterior, 1.5 mm lateral to the bregma 
and to extend 2.5 mm ventral from the surface of the skull. Cannulas were fixed to the skull with 
Plastics One cyanoacrylate gel adhesive and protected by a Plastics One guard. Mice were 
allowed 7 days to recover prior to treatment. 
 
Serum adenosine – As we have previously described. In brief, 500 μL of blood was 
mixed 1:2 with 138 mM NaCl, 8 mM Na2HPO4, 2 mM KH2PO4, 3 mM KCl, 5.9 mM NaHCO3, 
5.6 mM dextrose, 2.15 mM CaCl2, 1% DMSO, and 120 μM dipyridamole. Samples were 
centrifuged at 3650 x g for 10 min at 4⁰C and proteins precipitated by addition of 2% v/v of 70% 
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(12N) perchloric acid with re-centrifuged at 3650 x g for 10 min at 4⁰C. Adenosine was 
determined on a 5500 QTRAP LC/MS/MS (AB Sciex, Foster City, CA) with a 1200 series 
HPLC (Agilent Technologies, Santa Clara, CA). LC separation was performed on a Phenomenex 
Kinetex 2.6 u PFP column (4.6 x 100mm) (Torrence, CA). Mobile phase A was 0.1% formic 
acid in water. Mobile phase B was 0.1% formic acid in acetontrile. Flow rate was 0.3 mL/min 
and the linear gradient was: 0-1 min, 100% A; 5 min, 90% A; 10 min, 80% A; 12-18 min, 0% A; 
and 18.5-25 min, 100% A with an auto-sampler temperature of 5ºC. The injection volume was 5 
µL. Mass spectra were acquired with positive electrospray ionization with an ion spray voltage 
of 5500 V at a source temperature of 450 ºC. The curtain gas, ion source gas 1 and ion source gas 
2 were 35, 50, and 65, respectively. Multiple reaction monitoring was used to quantify adenosine 
m/z 268.1 --> m/z 136.1, inosine m/z 269.1 --> m/z 137.1 and internal standard caffeine m/z 
195.1 --> m/z 138.1. 
 
Activated caspase-1 labeling- Similar to methods we have previously described (Johnson 
et al, 2007; Chiu et al., 2012).  7 days after surgery, mice were injected with 50ng of Biotin-
YVAD-CMK ICV 30 min prior to hypoxia. After 2 hours of 6% oxygen, mice were taken out of 
the hypoxia chambers and allowed to reoxygenate for 4 hours. After reoxygenation, mice were 
euthanized using CO2 and perfused with 4% paraformaldehyde. Brains were removed from 0.7 
to -2.0 mm from the bregma coronally using a Mouse Brain Slice (Zivic Insttruments, Pittsburgh, 
PA). Slices were fixed in 4% paraformaldehyde for 24 hours then paraffin embedded.  5μm 
sections at 0.5 and -1.8 mm from the bregma were treated with antigen retrieval (BioGenex 
Antigen Retrieval Citra Plus) and blocked with 3% hydrogen peroxide in methanol and labeled 
with SS HRP Label (peroxidase-conjugated Strepavidin HK330-9KT), stained with liquid 3.3’-
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diaminobenzidine (DAB) chromogen (HK124-7K), counterstained with hematoxylin and 
mounted and coverslipped with the BioGenex i6000 Automated Staining system (BioGenex, San 
Ramon, CA). The entire slide was imaged at 40x with a NanoZoomer 2.0-HT (Hamamatsu, 
Bridgewater, NJ). Area and intensity of staining was measured using ImageJ (National Institute 
of Health). 
 
Open field test- Open field testing was performed as we have described (York et al., 
2012). In brief, mice were placed in a novel open field arena (66 cm length x 45.7 cm width x 
22.9 cm height) 30 min after adenosine injection. Lighting was positioned to create a 9 cm 
shadow from each side wall. Mice were video recorded for 5 min. Total distance traveled, time 
spent in the non-shadowed and shadowed areas of the arena were determined using Noldus 
Information Technology EthoVision XT 7. Results are presented as percent control of time (sec) 
in the non-shadowed area (center).  
 
Elevated zero-maze- Elevated zero-maze testing was performed as we have described 
(York et al., 2012). In brief, 30 min after adenosine injection mice were placed in a circular 
elevated zero-maze (22.5 cm in diameter, track width of 2.75 cm, elevated 33 cm above the 
floor). The maze was divided into two open quadrants and two enclosed quadrants. Mice were 
video recorded for 5 min. Total distance traveled, time spent in the open and closed arms of the 
maze were determined using Noldus Information Technology EthoVision XT 7. Results are 
presented as percent control of time (sec) in the open arms.   
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Statistics- All data are presented as mean ± SEM. Data was analyzed using Sigma Plot 
11.2 (Systat Software, Chicago, IL). To test for statistical differences, a one-way or two-way 
ANOVA was with repeated measurements where needed. Tukey’s test was used for post-hoc 
pair-wise multiple comparison procedures. Where indicated, raw data was transformed to attain 
equal variance. Statistical analysis included testing for time x treatment interactions when 
needed. Statistical significance was denoted at p < 0.05. 
 
Results 
 Hypoxia/reoxygenation-induced elevation in circulating adenosine- Fig.4.1 demonstrates 
that circulating adenosine is elevated by 264% 30 min after hypoxia and returned to basal levels 
by 2 hours. Main effect of hypoxia, p = 0.049, main effect of time, p = 0.031 main effect of 
interaction, p = 0.087 (normoxic vs. hypoxic at 0.5 hr, 0.45 ± 0.09 vs. 1.18 ± 0.28, p = 0.005; 
normoxic vs. hypoxic at 2 hr, 0.35 ± 0.14 vs. 0.40 ± 0.04, p = 0.854; normoxic 0.5 hr vs. 
normoxic 2 hr, 0.45 ± 0.09 vs. 0.35 ± 0.14, p = 0.705; hypoxic 0.5 hr vs. hypoxic 2 hr, 1.18 ± 
0.28 vs. 0.40 ± 0.04, p = 0.010).  
 
 Hypoxia/reoxygenation-induced activation of caspase-1 in neurons- Fig.4.2A&B are 
representative slides from the amygdala of normoxic and hypoxic mice when stained for active 
caspase-1. Fig 2C shows that the amygdala from hypoxic mice displayed a 4-fold increase in the 
area stained for active caspase-1 when compared to normoxic control (normoxic vs. hypoxia, 
2640.46 ± 300.42 vs. 11184.18 ± 872.36, p < 0.001). Fig.4.2D shows that the average staining 
intensity is 111% higher in hypoxic mice when compared to normoxic control (normoxic vs. 
hypoxic, 173.74 ± 3.97 vs. 193.01 ± 4.63, p = 0.030).  
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 Hypoxia/reoxygenation-induced anxiety is mediated via A2A AR- Fig.4.3A shows that 
mice exposed to hypoxia and allowed to reoxygenate for 2 hours displayed a 45% decrease in 
time spent in the center arena when compared to normoxic controls (normoxic WT vs. hypoxic 
WT, 100.00 ± 13.95 vs. 56.34 ± 12.45, p = 0.048), while A2A AR KO mice are protected against 
anxiety-like behavior (normoxic A2A AR KO vs. hypoxic A2A AR KO, 100.00 ± 28.25 vs. 
104.23 ± 19.84, p = 0.905). WT mice allowed to reoxygenate for 4 hours were not significantly 
different from normoxic controls (normoxic WT vs. hypoxic WT, 100.00 ± 12.03 vs. 69.90 ± 
17.92, p = 0.200; normoxic A2A AR KO vs. hypoxic A2A AR KO, 100.00 ± 21.74 vs. 92.05 ± 
19.25, p = 0.793). Fig.4.3B shows that mice exposed to hypoxia and allowed to reoxygenate for 
2 hours displayed a 86% decrease in time spent in the open arms of the elevated zero maze when 
compared to normoxic controls (normoxic WT vs. hypoxic WT, 100.00 ± 24.01 vs. 13.95 ± 9.45, 
p = 0.033), while A2A AR KO mice are protected against anxiety-like behavior (normoxic A2A 
AR KO vs. hypoxic A2A AR KO, 100.00 ± 34.63 vs. 161.64 ± 18.21, p = 0.166). WT mice 
allowed to reoxygenate for 4 hours were not significantly different from normoxic controls 
(normoxic WT vs. hypoxic WT, 100.00 ± 11.83 vs. 105.55 ± 28.17, p = 0.798; normoxic A2A 
AR KO vs. hypoxic A2A AR KO, 100.00 ± 14.46 vs. 217.88 ± 43.47, p = 0.038). 
 
Discussion 
 For the first time, we show, visually, that hypoxia/reoxygenation increases caspase-1 
activity in the neurons in the amygdala. Importantly, hypoxia/reoxygenation increased 
circulating adenosine and induces anxiety-like behaviors in WT but not A2A AR KO mice. 
These data strongly suggests a causative mechanism of hypoxia/reoxygenation-induced 
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adenosine release and subsequent increase in caspase-1 activity to produce IL-1β to elicit 
anxiogenic effects.  
 
ARDS is a severe reaction to lung injury or infection. It can cause inflammation due to 
decreased oxygen that has a 90% death rate when left untreated where survival increase to 50-
75% with treatment (Guérin et al., 2013). Extracellular adenosine concentration increases in 
ARDS due to increased degradation of purine nucleotides (Guckelberger et al., 2004; Hart et al., 
2008) where at low levels can serve as a neuroprotectant. Similar to the study by Hagberg et al. 
(Hagberg et al., 1987), Fig.4.1 shows that circulating adenosine is increased after hypoxia, 
although not to the same degree. This discrepancy may be due to the fact that Hagberg used 
complete brain ischemia for 15 min, where oxygen supply is cut off, and sampled via 
microdialysis from the brain, while this study measured circulating adenosine after 6% hypoxia. 
Our less severe treatment may have caused a lower increase in adenosine. Our normoxic controls 
showed concentrations near the range published by Rudolph et al. (Rudolphi et al., 1992), 
proving validity to our collection method.   
 
 As we have previously published, hypoxia/reoxygenation leads to a region-specific 
increase in caspase-1 activity (Chiu et al., 2012). This was previously measured colorimetrically 
for changes in activity in vitro. Here, we present a novel method of detecting caspase-1 in the 
brain. Biotin-YVAD-CMK is a caspase-1 specific inhibitor that covalently and irreversibly binds 
to mature but not pro-caspase-1 (Gao et al., 2008l Wu et al., 2010). We see that labeling biotin 
with strepavidin-HRP and staining with DAB allows us to visualize active caspase-1 in vivo. 
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When looking at various regions of the brain, we see that the amygdala (Fig.4.2), and parts of the 
striatum, but not the hippocampus (data not shown), showed increase caspase-1 staining due to 
hypoxia. This confirms our finding from 2012 that hypoxia/reoxygenation activates caspase-1 in 
specific regions rather than the whole brain. 
 
 Interestingly, we see that caspase-1 activity is stained most visibly in neurons. 
Previously, we saw that inhibition of A2A AR signaling can be protective against 
hypoxia/reoxygenation- (Chiu et al., 2012) and adenosine-induced caspase-1 activation, and 
here, we see that A2A AR KO mice are protected against hypoxia/reoxygenation-induced 
anxiety-like behavior, we expected to see more ubiquitous activation due to the presence of A2A 
AR in microglia (Orr et al., 2009), astrocytes (Brambilla et al., 2003), endothelial cells (Mills et 
al., 2011), and oligodentrocytes (Melani et al., 2009). While we expected to see staining in 
immune cells due to caspase-1 and IL-1β regulation, this is not too surprising because, as we 
have previously shown, 6% hypoxia/reoxygenation does not elicit gliosis (Chiu et al., 2012) or 
cell death (Johnson et al., 2007).  
 
 As we see in Fig.4.2, the amygdala of hypoxic mice displayed increased active caspase-1 
staining. This suggests an increase in IL-1β production, where in the brain can be anxiogenic 
(Song et al., 2003). In humans, anxiety and mood disorders also coincide with elevated plasma 
adenosine (Cella et al., 2011, Duley et al., 2000). Importantly, we and others (Rosin et al., 1998) 
have shown that the A2A AR is primarily expressed in the amygdala and striatum. In fact, Tye et 
al. demonstrated that neurons in the amygdala regulate anxiety-like behaviors (Tye et al., 2011). 
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This is shown in Fig.4.3, where hypoxia/reoxygenation induced anxiety-like behaviors in the 
open field test as well as the elevated zero maze. Furthermore, A2A AR KO mice were protected 
against this anxiogenic effect, further suggesting the importance of the A2A AR in regulating 
hypoxia/reoxygenation-induced behavioral changes.  
 
 In conclusion, pathological states such as sterile infection and hypoxia/ischemia can not 
only induce inflammatory responses but also increase in extracellular adenosine (Winn et al., 
1981, Karmouty-Quintana et al., 2013) to hyperpolarize and inhibit neuronal activity (Lambert & 
Teyler, 1991, Prince & Stevens, 1992). The data presented here demonstrates that 
hypoxia/reoxygenation induces an elevation in circulating adenosine that can act upon the 
neurons in the amygdala to increase caspase-1 activity and subsequently generate IL-1β-induced 
anxiety-like behaviors.  
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Fig.1.1. Purine metabolism and adenosine signaling pathway.
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Table 1.1. Effects of adenosine in on neurological disorders 
Disease Experimental 
Model 
Interaction with  Adenosine Reference 
Type 1 
Diabetes 
Nonobese diabetic 
rats (stretozotocin-
induced 
hyperglycemia) 
hippocampal slice 
culture 
Diabetic-like state enhanced 
adenosine-evoked inhibition 
Morrison et al., 1992 
    
Alzheimer's 
Disease 
Alzheimer's 
Disease Patients 
AD patients showed increased 
expression of A1 and A2A 
receptors 
Angulo et al., 2003 
A1 agonist increased production 
of soluble amyloid precursor 
protein 
    
 Cultured Neurons Caffeine protects against β-
amyloid-induced toxicity 
Dall'Igna et al., 2003 
  A2A but not A1 antagonism 
protected against  β-amyloid-
induced toxicity 
 
    
 ICV administration 
of  β-amyloid 
(Mouse) 
12-d caffeine treatment in 
drinking water plus acute caffeine 
injection prevented  β-amyloid-
induced cognitive impairment 
Dall'Igna et al., 2007 
  4-d caffeine of A2A antagonist 
injection prevented  β-amyloid-
induced cognitive impairment 
 
    
 Striatum from AD 
patients 
Loss of A1 receptors in AD 
striatum paralleled a loss of 
choline acetyltransferase activity 
Ikeda et al., 1993 
    
 APPsw transgenic 
mice 
Daily caffeine intake improved 
behavior and reduced 
hippocampal β-amyloid  
Arendash et al., 2006 
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Table 1.1 cont. Effects of adenosine in on neurological disorders 
Disease Experimental 
Model 
Interaction with  Adenosine Reference 
Parkinson's 
Disease 
Various Heteromeric antagonistic D2/A2A 
receptors 
Boison, 2007 
   
 A2A opposes the action of D2 on 
GABAergic neurons 
Schwarzschild et al., 
2006 
  Heteromeric synergistic 
A2A/mGlu receptors 
 
  Slow down progression of PD  
    
  KW-6002 (A2A antagonist) 
shows potential in phase IIb and 
III in PD patients 
Jacobson & Gao, 2006 
    
Depression Various Adenosine antagonism delayed 
hypoxia-induced depression 
Fowler, 1989 
    
  Adenosine antagonism exhibits 
antidepressant-like properties 
Sarges et al., 1990 
    
  A2A KO displayed less 
depressive-like behavior when 
compared to wild-type control 
Yacoubi et al., 2001 
  A2A antagonism elicited 
antidepressant-like properties 
 
  D2 antagonist prevented A2A 
antagonist's antidepressive-like 
properties 
 
    
Ischemia/ 
Hypoxia 
Various Adenosine rapidly increase after 
hypoxia and ischemia 
Frenguelli et al., 2007 
   
  Adenosine antagonism delayed 
hypoxia-induced depression 
Fowler, 1989 
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Fig.2.1. Restoration of memory recall after acute hypoxia. (A) Wild type mice were 
trained in memory formation using novel object recognition 1 h prior to hypoxia. Mice were then 
exposed to normoxia or hypoxia for 2 hrs. Memory recall (percent investigation) was measured 
at the reoxygenation time points indicated. Results are expressed as means ± s.e.m.; n = 8. Bars 
without a common superscript are different (p < 0.05). (B) Mice were treated as in A and 
spontaneous locomotor activity (total distance traveled) was measured at the reoxygenation time 
points indicated. Results are expressed as means ± s.e.m.; n =6. Bars without a common 
superscript are different (p < 0.05). 
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Fig.2.2. Memory formation recovers more slowly than memory recall after acute hypoxia. 
(A) Wild type mice were exposed to normoxia (Norm) or hypoxia for 2 hrs. After hypoxia, mice 
were trained in memory formation using novel object recognition 1 h prior to the time points 
indicated. Memory recall (percent investigation) was measured at the reoxygenation time points 
indicated. Results are expressed as means ± s.e.m.; n = 6-8. Bars without a common superscript 
are different (p < 0.05). (B) Mice were treated as in A. Mice were trained in memory formation 
using cued fear conditioning after 4 hrs of reoxygenation. Memory recall (immobility) was 
measured after 5 and 52 h of reoxygenation. Results are expressed as means ± s.e.m.; n =4. Bars 
without a common superscript are different (P < 0.05). (C) Mice were treated as in A. Perfect 
alternations were measured after 4, 52, and 76 h of reoxygenation. Results are expressed as 
means ± s.e.m.; n =4.  
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Fig.2.3. Knockout of IL-1R1 improves memory formation and locomotion while blunting 
activation of ERK1/2 and p38 MAPK- (A) Wild type (WT) or IL-1R1 KO mice were exposed to 
normoxia or hypoxia for 2 hrs. Mice were trained in memory formation using novel object 
recognition after 4 hrs of reoxygenation. Memory recall (percent investigation) was measured 
after 5 hrs of reoxygenation. Results are expressed as means ± s.e.m.; n = 4. Bars without a 
common superscript are different (p < 0.05). (B) WT mice treated with/without IP IL-1RA were 
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exposed to normoxia or hypoxia as in A and memory was tested as in A. Results are expressed as 
means ± s.e.m.; n = 6. Bars without a common superscript are different (p < 0.05). (C) WT mice 
treated with/without ICV Ac-YVAD-CMK were exposed to normoxia or hypoxia as in A and 
memory was tested as in A. Results are expressed as means ± s.e.m.; n = 6. Bars without a 
common superscript are different (p < 0.05). (D) WT or IL-1R1 KO mice were treated as in A 
and spontaneous locomotor activity (total distance traveled) was measured at the reoxygenation 
time points indicated. Results are expressed as means ± s.e.m.; n =4. Bars without a common 
superscript are different (p < 0.05). (E) WT and IL-1R1 KO mice were exposed to normoxia or 
hypoxia as in A. Brain p-pERK1/2, p-p38 MAPK and p-JNK were measured 1 hr after hypoxia. 
Results are expressed as means ± s.e.m.; n = 6-9. Bars without a common superscript are 
different (p < 0.05). 
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Fig.2.4                                                                        
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Fig.2.4 (cont.). AR blockade prevents hypoxia-dependent activation of caspase 1 in the 
brain. (A) Wild type mice were exposed to normoxia or hypoxia for 2 hrs. Caspase 1 activity was 
measured at the reoxygenation time points indicated. Results are expressed as means ± s.e.m.; n 
= 4. Bars without a common superscript are different (p < 0.05). (B) Wild type mice treated 
with/without caffeine were exposed to normoxia or hypoxia as in A and caspase 1 activity 
measured 1 hr after reoxygenation. Results are expressed as means ± s.e.m.; n = 4. Bars without 
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a common superscript are different (p < 0.05). (C) Wild type mice treated with/without 8-
cyclopentyl-1, 3-dipropylxanthine + 3, 7-dimethyl-1-propargylxanthine (A1/A2A antag) were 
exposed to normoxia or hypoxia as in A and caspase 1 activity measured 1 hr after 
reoxygenation. Results are expressed as means ± s.e.m.; n = 4. Bars without a common 
superscript are different (p < 0.05). (D) Wild type mice treated with/without NAC were exposed 
to normoxia or hypoxia as in A and caspase 1 activity measured 1 hr after reoxygenation. Results 
are expressed as means ± s.e.m.; n = 6. Bars without a common superscript are different (p < 
0.05). (E) Wild type mice were perfused with the adenosine concentrations indicated. Caspase 1 
activity was measured 1 hr after perfusion. Results are expressed as means ± s.e.m.; n = 6. Bars 
without a common superscript are different (p < 0.05). (F) Wild type mice were perfused 
with/without 50 µM adenosine + 500 µM caffeine. Caspase 1 activity was measured 1 hr after 
perfusion. Results are expressed as means ± s.e.m.; n = 6. Bars without a common superscript are 
different (p < 0.05). (G) Wild type mice were perfused with/without 50 µM adenosine + 500 µM 
NAC. Caspase 1 activity was measured 1 hr after perfusion. Results are expressed as means ± 
s.e.m.; n = 6. Bars without a common superscript are different (p < 0.05). 
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Fig.2.5. Hypoxia induces brain region-specific activation of caspase 1- (A) Wild type 
mice were exposed to normoxia or hypoxia for 2 hrs. Caspase 1 activity was measured in the 
amygdala and hippocampus 1 hr after reoxygenation Results are expressed as means ± s.e.m.; n 
= 4. Bars without a common superscript are different (p < 0.05). (B) Wild type (WT) mice and 
IL-1R1 KO mice were treated as in A. Immunohistochemistry was performed for GFAP at 1 and 
6 hrs after reoxygenation. Representative images of the amygdala (n = 3). 
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Fig.2.6. AR blockade speeds recovery of memory formation after hypoxia. (A) Wild type 
mice treated with/without caffeine were exposed to normoxia or hypoxia for 2 hrs. Mice were 
trained in memory formation using novel object recognition after 4 hrs of reoxygenation. 
Memory recall (percent investigation) was measured after 5 hrs of reoxygenation. Results are 
expressed as means ± s.e.m.; n = 6. Bars without a common superscript are different (p < 0.05). 
(B) Wild type mice treated with/without 8-cyclopentyl-1, 3-dipropylxanthine + 3, 7-dimethyl-1-
propargylxanthine (A1/A2A antag) were exposed to normoxia or hypoxia as in A and memory 
tested as in A. Results are expressed as means ± s.e.m.; n = 6. Bars without a common 
superscript are different (p < 0.05). 
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Table 2.1 Impact of reoxygenation on the 
glutathione to glutathione disulfide 
(GSH/GSSG) ratio in the brain  
Treatment Normoxic 
Reoxygenation 
(1 h) 
Saline 1.00 ± 0.21a  0.49 ± 0.12b  
Caffeine 0.88 ± 0.15a  0.87 ± 0.10a  
NAC 0.82 ± 0.02 a 1.03 ± 0.03 a 
 
 Wild type mice were exposed to normoxia or hypoxia for 2 hrs. Whole brains were harvested 
and analyzed for GSH and GSSG concentrations. Results are expressed as relative change in 
GSH/GSSG ratio, means ± s.e.m.; n = 4. Results within individual rows without a common 
superscript are different (p < 0.05). 
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 Fig.3.1 Inhibition of potassium efflux prevents adenosine-dependent activation of 
caspase-1 in the brain. (A) Wild type mice were perfused with or without PBK and/or adenosine 
and activity of caspase-1 measured. Results are expressed as means ± s.e.m.; n = 4. Bars without 
a common superscript are different (p < 0.05). (B) Wild type mice were perfused with or without 
glyburide and/or adenosine and activity of caspase-1 measured. Results are expressed as means ± 
s.e.m.; n = 4. Bars without a common superscript are different (p < 0.05).  
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 Fig.3.2 The PKA inhibitor KT5720 blocks activation of caspase-1 by adenosine. (A) Wild 
type mice were perfused with or without KT5720 and/or adenosine and activity of caspase-1 
measured. Results are expressed as means ± s.e.m.; n = 4. Bars without a common superscript 
are different (p < 0.05). (B) Wild type mice were perfused with or without adenosine and activity 
of PKA. Results are expressed as means ± s.e.m.; n = 4. Bars without a common superscript are 
different (p < 0.05). (C) Wild type mice were perfused with or without adenosine and the 
concentration of cAMP measured. Results are expressed as means ± s.e.m.; n = 4. Bars without a 
common superscript are different (p < 0.05).  
PB
S
Ad
en
os
in
e
KT
57
20
Ad
en
os
in
e 
+ 
KT
57
20
C
a
s
p
a
s
e
- 1
 A
c
ti
v
it
y
 (
R
e
la
t i
v
e
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
a
b
a a
A
B
PB
S
Ad
en
os
in
e
P
K
A
 A
c
ti
v
it
y
 (
R
e
l a
ti
v
e
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
a
b
C
PB
S
Ad
en
os
in
e
c
A
M
P
 C
o
n
c
e
n
tr
a
ti
o
n
 (
R
e
la
ti
v
e
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
a
b
79 
 
  
 Fig.3.3 Activation of caspase-1 by adenosine is blocked by selective A2A AR antagonism 
and in A2A AR KO mice. (A) Wild type mice were perfused with or without 8-(3-
Chlorostyryl)caffeine (CSC) and/or and activity of caspase-1 measured. Results are expressed as 
means ± s.e.m.; n = 4. Bars without a common superscript are different (p < 0.05). (B) Wild type 
and A2A AR KO mice were perfused with or without adenosine and activity of caspase-1 
measured. Results are expressed as means ± s.e.m.; n = 4. Bars without a common superscript 
are different (p < 0.05).  
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 Fig.3.4 (cont.) Adenosine activates caspase-1 in the brain while reducing locomotor 
activity and food intake. (A) Wild type mice were treated with or without IP adenosine and 
activity of caspase-1 in brain measured 15 min after adenosine administration. Results are 
expressed as means ± s.e.m.; n = 4. Bars without a common superscript are different (p < 0.05). 
Data was analyzed using Kruskal-Wallis One Way Analysis of Variance on Ranks to attain equal 
variance. (B) C57 WT mice were treated with or without IP adenosine and locomotion measured 
at 15, 30, 45, 60, 75, 90 and 105 mins after adenosine administration. Results are expressed as 
means ± s.e.m. versus saline injected controls; n = 8. *p < 0.05. (C) Casp-1 KO mice were 
treated with or without IP adenosine and locomotion measured at 15, 30, 45 and 60 mins after 
adenosine administration. Results are expressed as means ± s.e.m. versus saline injected controls; 
n = 8. (D) IL-1R1 KO mice were treated with or without IP adenosine and locomotion measured 
at 15, 30, 45 and 60 mins after adenosine administration. Results are expressed as means ± s.e.m. 
versus saline injected controls; n = 8. (E) BALB/c WT mice were treated with or without IP 
adenosine and locomotion measured at 15, 30, 45 and 60 mins after adenosine administration. 
Results are expressed as means ± s.e.m. versus saline injected controls; n = 5. *p < 0.05. (F) 
A2A AR KO mice were treated with or without IP adenosine and locomotion measured at 15, 30, 
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45 and 60 mins after adenosine administration. Results are expressed as means ± s.e.m. versus 
saline injected controls; n = 5. (G) C57 WT, Casp-1 KO and IL-1R1 KO mice were treated with 
or without IP adenosine and food intake measured for 60 min following adenosine 
administration. Results are expressed as means ± s.e.m. versus saline injected controls; n = 5-8. 
*p < 0.05. (H) BALB/c WT and A2A AR KO mice were treated with or without IP adenosine 
and food intake measured for 60 min following adenosine administration. Results are expressed 
as means ± s.e.m. versus saline injected controls l; n = 8. *p < 0.05. 
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 Fig.3.5 Central administration of the caspase-1 inhibitor Ac-YVAD-CMK blocks 
adenosine-induced reductions in locomotor activity and food intake. (A) C57 WT mice were 
treated with or without ICV Ac-YVAD-CMK and IP adenosine. Locomotion was measured at 0, 
15, 30 and 45 mins after adenosine administration. Results are expressed as means ± s.e.m.; n = 
5. Bars without a common superscript are different (p < 0.05). (B) C57 WT mice were treated 
with or without ICV Ac-YVAD-CMK and IP adenosine. Food intake was measured for 60 min 
after adenosine administration. Results are expressed as means ± s.e.m.; n = 5. Bars without a 
common superscript are different (p < 0.05).  
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 Fig.3.6 Adenosine causes anxiety-like behavior. (A) C57 WT, Casp-1 KO, IL-1R1 KO, 
BALB/c WT and A2A AR KO mice were treated with or without IP adenosine and time spent in 
the center area was measured 30 min after adenosine administration. Results are expressed as 
means ± s.e.m. versus saline injected genotype control; n = 3-7. *p < 0.05. (B) C57 WT, Casp-1 
KO, IL-1R1 KO, BALB/c WT and A2A AR KO mice were treated with or without IP adenosine. 
Total distance traveled in the arena was measured 30 min after adenosine administration. Results 
are expressed as means ± s.e.m. versus saline injected genotype control; n = 3-7. (C) C57 WT, 
Casp-1 KO, IL-1R1 KO, BALB/c WT and A2A AR KO mice were treated with or without IP 
adenosine and time spent in the open arms of the elevated zero-maze were measured 30 min after 
adenosine administration. Results are expressed as means ± s.e.m. versus saline injected 
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genotype control; n = 4-6. *p < 0.05. Data was analyzed using Kruskal-Wallis One Way 
Analysis of Variance on Ranks to attain equal variance. (D) C57 WT, Casp-1 KO, IL-1R1 KO, 
BALB/c WT and A2A AR KO mice were treated with or without IP adenosine. Total distance 
traveled in the elevated zero-maze was measure 30 min after adenosine administration. Results 
are expressed as means ± s.e.m. versus saline injected genotype control; n = 4-6.  
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Table 3.1 Adenosine increases IL-1β protein 
(pg/μg) in the brain but not the liver 
Tissue 
Saline  
(mean ± SEM) 
Adenosine 
(Mean ± SEM) 
Brain 0.71 ± 0.14a 1.58 ± 0.32 b 
Liver 2.00 ± 0.63 1.15 ± 0.29 
Results are expressed as means; n = 6. Values 
without a common superscript are different; p 
< 0.05 
 
Table 3.2 Differential 
expression of A2A AR mRNA 
Regions 
Fold Change 
Mean (S.E.M) 
Whole Brain 1.00 (0.12)ab 
Amygdala 1.31 (0.38)ab 
Hippocampus 0.13 (0.03)cd 
Results are expressed as 
means; n = 4-6. Values without 
a common superscript are 
different; p < 0.05  
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 Fig.4.1. Hypoxia/reoxygenation-induced elevation in circulating adenosine. Wild type 
mice were exposed to normoxia (Normoxic) or hypoxia (Hypoxic) for 2 hrs. After hypoxia, mice 
were allowed to reoxygenate for 0.5 or 2 hrs as indicated before being euthanized and circulating 
adenosine concentration was measured. Results are expressed as means ± s.e.m.; n = 4-8. *p < 
0.05.  
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 Fig.4.2. Hypoxia/reoxygenation-induced activation of caspase-1 in neurons. (A&B) Wild 
type mice were exposed to normoxia (Normoxic) or hypoxia (Hypoxic) for 2 hours. After 
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hypoxia, mice were allowed to reoxygenate for 4 hrs before euthanized and brain sections were 
taken. Representative images of the amygdala (n = 3-4). (C) Mice were treated as A. 
Immunohistochemistry was performed for Biotin-YVAD-CMK. Area of staining was measured 
using ImageJ. Results are expressed as means ± s.e.m.; n = 3-4. *p < 0.05. (D) Mice were treated 
as A. Immunohistochemistry was performed for Biotin-YVAD-CMK. Mena intensity of staining 
was measured using ImageJ. Results are expressed as means ± s.e.m.; n = 3-4. *p < 0.05. 
90 
 
 
 
 Fig.4.3. Hypoxia/reoxygenation-induced anxiety is mediated via A2A AR. (A) BALB/c 
WT and A2A AR KO mice were exposed to normoxia (Normoxic) or hypoxia (Hypoxic) and 
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time spent in the center area was measured after 2 and 4 hrs of reoxygenation as indicated. 
Results are expressed as means ± s.e.m. versus normoxic genotype control; n = 4-6. *p < 0.05. 
(B) BALB/c WT and A2A AR KO mice were exposed to normoxia (Normoxic) or hypoxia 
(Hypoxic) and time spent in the open arms of the elevate-zero maze was measured after 2 and 4 
hrs of reoxygenation as indicated. Results are expressed as means ± s.e.m. versus normoxic 
genotype control; n = 3-8. *p < 0.05. 
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